<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//ES//DTD journal article DTD version 5.1.0//EN//XML" "art510.dtd" [<!ENTITY gr1 SYSTEM "gr1" NDATA IMAGE><!ENTITY gr2 SYSTEM "gr2" NDATA IMAGE>]><article docsubtype="rev"><item-info><jid>PCL</jid><aid>725</aid><ce:pii>S0031-3955(10)00026-X</ce:pii><ce:doi>10.1016/j.pcl.2010.02.004</ce:doi><ce:copyright type="full-transfer" year="2010">Elsevier Inc.</ce:copyright></item-info><ce:floats><ce:figure id="fig1"><ce:label>Fig.&nbsp;1</ce:label><ce:caption><ce:simple-para>When a cell membrane is injured, the arachidonic acid pathway is activated to initiate the local inflammatory response through the production of prostaglandins, thromboxanes, and leukotrienes. Their activation, however, requires the enzymes COX and LOX. The NSAIDs can block COX action and thereby prevent the formation of the COX-derived inflammatory mediators. 5-HPETE, 5-hydroperoxyeicosatetraenoic acid; LTC<ce:inf>4</ce:inf>, leukotriene C4; PGE<ce:inf>2</ce:inf>, prostaglandin E2; PGF<ce:inf>2</ce:inf>, prostaglandin F2; PGI<ce:inf>2</ce:inf>, prostacyclin; TXA<ce:inf>2</ce:inf>, thromboxane.</ce:simple-para></ce:caption><ce:source><ce:italic>From</ce:italic> Maroon J, Bost J, Borden M, et&nbsp;al. Natural anti-inflammatory agents for pain relief in athletes. Neurosurg Focus 2006;21(4):E11; with permission.</ce:source><ce:link locator="gr1"/></ce:figure><ce:figure id="fig2"><ce:label>Fig.&nbsp;2</ce:label><ce:caption><ce:simple-para>The COX enzyme can exist in 2 forms: COX-1, constitutional or existing in small amounts at all times; or COX-2, inducible or only present during the inflammatory response. By selectively blocking only the COX-2&ndash;produced inflammatory prostaglandins, COX-2&ndash;inhibiting medications were believed to be superior to nonselective COX-1 and -2 inhibitors, and they were thought to have fewer gastric side effects.</ce:simple-para></ce:caption><ce:source><ce:italic>From</ce:italic> Maroon J, Bost J, Borden M, et&nbsp;al. Natural anti-inflammatory agents for pain relief in athletes. Neurosurg Focus 2006;21(4):E11; with permission.</ce:source><ce:link locator="gr2"/></ce:figure><ce:table id="tbl1" frame="topbot" colsep="0" rowsep="0"><ce:label>Table 1</ce:label><ce:caption><ce:simple-para>Salicylated NSAIDs</ce:simple-para></ce:caption><ce:source><ce:italic>Data from</ce:italic> Refs.<ce:cross-refs refid="bib13 bib14 bib40"><ce:sup>13,14,40</ce:sup></ce:cross-refs></ce:source><tgroup cols="3"><colspec colnum="1" colname="col1"/><colspec colnum="2" colname="col2"/><colspec colnum="3" colname="col3"/><thead><row rowsep="1" valign="top"><entry>Drug</entry><entry>Onset of Action and Duration of Effect (hours)</entry><entry>Comments</entry></row></thead><tbody><row valign="top"><entry>Diflunisal</entry><entry>Onset: &sim;1<ce:br/>Duration:<ce:br/>Analgesic: 8&ndash;12<ce:br/>Anti-inflammatory: &le;12</entry><entry>&sim;4&ndash;5 times more potent analgesic and anti-inflammatory effects than aspirin; fewer platelet/GI side effects compared with aspirin; not metabolized to salicylic acid</entry></row><row valign="top"><entry>Salsalate</entry><entry>Onset: N/A<ce:br/>Duration: N/A</entry><entry>Fewer platelet and GI side effects than aspirin</entry></row><row valign="top"><entry>Choline magnesium trisalicylate</entry><entry>Onset: &sim;2<ce:br/>Duration: N/A</entry><entry>Less effect on platelet aggregation and fewer GI side effects than aspirin; avoid or use with caution in renal insufficiency due to magnesium content</entry></row><row valign="top"><entry>Magnesium salicylate</entry><entry>Onset: N/A<ce:br/>Duration: 4&ndash;6</entry><entry>Available OTC; less effect on platelet aggregation and fewer GI side effects than aspirin; avoid or use with caution in renal insufficiency due to magnesium content</entry></row></tbody></tgroup><ce:legend><ce:simple-para><ce:italic>Abbreviations:</ce:italic> GI, gastrointestinal; N/A, no data available; OTC, over-the-counter.</ce:simple-para></ce:legend></ce:table><ce:table id="tbl2" frame="topbot" colsep="0" rowsep="0"><ce:label>Table 2</ce:label><ce:caption><ce:simple-para>Common doses of salicylated NSAIDs</ce:simple-para></ce:caption><ce:source><ce:italic>Data from</ce:italic> Refs.<ce:cross-refs refid="bib19 bib40"><ce:sup>19,40</ce:sup></ce:cross-refs></ce:source><tgroup cols="4"><colspec colnum="1" colname="col1"/><colspec colnum="2" colname="col2"/><colspec colnum="3" colname="col3"/><colspec colnum="4" colname="col4"/><thead><row rowsep="1" valign="top"><entry>Generic Name</entry><entry>Trade Name</entry><entry>Adult Dose</entry><entry>Comments</entry></row></thead><tbody><row valign="top"><entry>Diflunisal</entry><entry/><entry>1000 mg, then 500 mg every 12 h<ce:br/>Age &ge;12 y: same as adult</entry><entry>Do not crush or chew tablet; maximum 1.5 g daily</entry></row><row valign="top"><entry>Salsalate</entry><entry>Amigesic</entry><entry>1 g 3 times daily</entry><entry>Do not crush tablets; urinary acidification can decrease clearance and increase risk for toxicity</entry></row><row valign="top"><entry>Choline magnesium trisalicylate</entry><entry>Trilisate</entry><entry>500 mg&ndash;1.5 g 2&ndash;3 times daily</entry><entry>Maintenance dose: 1&ndash;4.5 g daily; available as liquid formulation; urinary acidification can decrease clearance and increase risk for toxicity</entry></row><row valign="top"><entry>Magnesium salicylate</entry><entry>Doan&apos;s Extra Strength<ce:br/>Keygesic</entry><entry>Doan&apos;s (467 mg): 2 caplets every 6 h as needed<ce:br/>Keygesic (650 mg): 1 tablet every 4 h as needed<ce:br/>Age &ge;12 y: same as adult</entry><entry>Available OTC; Doan&apos;s: maximum 8 caplets in 24 h<ce:br/>Keygesic: maximum 4 tablets in 24 h</entry></row></tbody></tgroup></ce:table><ce:table id="tbl3" frame="topbot" colsep="0" rowsep="0"><ce:label>Table 3</ce:label><ce:caption><ce:simple-para>Nonsalicylated NSAIDs</ce:simple-para></ce:caption><ce:source><ce:italic>Data from</ce:italic> Refs.<ce:cross-refs refid="bib13 bib14 bib40"><ce:sup>13,14,40</ce:sup></ce:cross-refs></ce:source><tgroup cols="3"><colspec colnum="1" colname="col1"/><colspec colnum="2" colname="col2"/><colspec colnum="3" colname="col3"/><thead><row rowsep="1" valign="top"><entry>Drug</entry><entry>Onset of Action and Duration of Effect</entry><entry>Comments</entry></row></thead><tbody><row valign="top"><entry namest="col1" nameend="col3">Propionic acids</entry></row><row valign="top"><entry>Fenoprofen</entry><entry>Onset: &sim;72 h<ce:br/>Duration: 4&ndash;6 h</entry><entry>&sim;15% of patients will have side effects but few stop therapy</entry></row><row valign="top"><entry>Flurbiprofen</entry><entry>Onset: &sim;1&ndash;2 h<ce:br/>Duration: variable</entry><entry>Strong inhibitor of CYP 450 2C9 isoenzyme; substrate CYP 2C9 (minor)</entry></row><row valign="top"><entry>Ibuprofen</entry><entry>Onset:<ce:br/>Analgesic: 0.5&ndash;1 h<ce:br/>Anti-inflammatory: &le;7 d<ce:br/>Duration: 4&ndash;6 h</entry><entry>Strong inhibitor of CYP 450 2C9 isoenzyme; substrate CYP 2C9 and 2C19 (minor); equal efficacy to aspirin; &sim;10%&ndash;15% of patients stop therapy due to side effects</entry></row><row valign="top"><entry>Ketoprofen</entry><entry>Onset: 0.5 h<ce:br/>Duration: 6 h</entry><entry>&sim;30% of patients develop side effects with GI as the most common</entry></row><row valign="top"><entry>Naproxen</entry><entry>Onset:<ce:br/>Analgesic: 1 h<ce:br/>Anti-inflammatory: 2 weeks<ce:br/>Duration:<ce:br/>Analgesic: &le;7 h<ce:br/>Anti-inflammatory: &le;12 h</entry><entry>Available as OTC product; more potent than aspirin in vitro, likely better tolerated than aspirin; may provide cardioprotection for some individuals with heart disease</entry></row><row valign="top"><entry>Oxaprozin</entry><entry>Onset: &sim;0.5&ndash;4 h<ce:br/>Duration: variable</entry><entry>Slower onset of effects compared with others; longer half-life allows for once a day dosing</entry></row><row valign="top"><entry namest="col1" nameend="col3">Acetic acids</entry></row><row valign="top"><entry>Diclofenac</entry><entry>Onset: 1&ndash;4.5 h<ce:br/>Duration: 12&ndash;24 h</entry><entry>More potent than aspirin; side effects experienced by &sim;20% and 2% stop therapy; &sim;15% of patients will experience an increase in liver function test; available as topical patch and gel as well as in combination with misoprostol</entry></row><row valign="top"><entry>Etodolac</entry><entry>Onset:<ce:br/>Analgesic: 2&ndash;4 h<ce:br/>Anti-inflammatory: several days<ce:br/>Duration: N/A</entry><entry>In vitro COX-2 selectivity; 100 mg of etodolac provides similar efficacy to aspirin 650 mg but may have fewer side effects</entry></row><row valign="top"><entry>Sulindac</entry><entry>Onset: N/A<ce:br/>Duration: N/A</entry><entry>Similar efficacy to aspirin; active metabolite; side effects experienced &sim;20% GI and &sim;10% CNS</entry></row><row valign="top"><entry>Tolmetin</entry><entry>Onset:<ce:br/>Analgesic: 1&ndash;2 h<ce:br/>Anti-inflammatory: days to weeks<ce:br/>Duration: variable</entry><entry>Similar efficacy to aspirin; side effects experienced by &sim;25%&ndash;40% and 5%&ndash;10% stop therapy</entry></row><row valign="top"><entry>Indomethacin</entry><entry>Onset: &sim;0.5 h<ce:br/>Duration: 4&ndash;6 h</entry><entry>Compared with aspirin10&ndash;40 times more potent; incidence of side effects 3%&ndash;50%; &sim;20% of patients stop therapy due to side effects</entry></row><row valign="top"><entry>Ketorolac</entry><entry>Onset:<ce:br/>Analgesic: &sim;10 min (IM)<ce:br/>Duration:<ce:br/>Analgesic: 6&ndash;8 h</entry><entry>Maximum duration of 5 d (oral and parenteral); strong analgesic activity but weak anti-inflammatory activity; may be given parenterally for acute pain</entry></row><row valign="top"><entry namest="col1" nameend="col3">Oxicams</entry></row><row valign="top"><entry>Meloxicam</entry><entry>Onset: N/A<ce:br/>Duration: N/A</entry><entry>CYP 450 inhibitor of isoenzyme 2C9 (weak); substrate CYP 2C9 and 3A4 (minor); some COX-2 selective action at lower end of dosing range</entry></row><row valign="top"><entry>Piroxicam</entry><entry>Onset: &sim;1 h<ce:br/>Duration: variable</entry><entry>Equal efficacy to aspirin; may be better tolerated than aspirin; &sim;20% of patients will experience side effects and 5% will stop therapy</entry></row><row valign="top"><entry namest="col1" nameend="col3">Naphthylalkanone</entry></row><row valign="top"><entry>Nabumetone</entry><entry>Onset: &sim;72 h<ce:br/>Duration: variable</entry><entry>Prodrug; some COX-2 selectivity; has less GI toxicity than most NSAIDs</entry></row><row valign="top"><entry namest="col1" nameend="col3">Fenamate</entry></row><row valign="top"><entry>Meclofenamate</entry><entry>Onset: &lt;1 h<ce:br/>Duration: &le;6 h</entry><entry>Equal efficacy to aspirin; &sim;25% of patients will experience gastrointestinal adverse events</entry></row><row valign="top"><entry>Mefenamic acid</entry><entry>Onset: N/A<ce:br/>Duration: &le;6 h</entry><entry>CYP 450 inhibitor of isoenzyme 2C9 (strong); substrate CYP 2C9 (minor)</entry></row><row valign="top"><entry namest="col1" nameend="col3">COX-2 inhibitor</entry></row><row valign="top"><entry>Celecoxib</entry><entry>Onset:<ce:br/>Analgesic: &sim;0.75 h to several months<ce:br/>Duration: &sim;4&ndash;8 h</entry><entry>CYP 450 inhibitor of isoenzymes 2C8 (moderate) and 2D6 (weak); substrate CYP 2C9 (major) and 3A4 (minor); does not inhibit platelet aggregation</entry></row></tbody></tgroup></ce:table><ce:table id="tbl4" frame="topbot" colsep="0" rowsep="0"><ce:label>Table 4</ce:label><ce:caption><ce:simple-para>Common doses of nonsalicylated NSAIDs</ce:simple-para></ce:caption><ce:source><ce:italic>Data from</ce:italic> Refs.<ce:cross-refs refid="bib19 bib40"><ce:sup>19,40</ce:sup></ce:cross-refs></ce:source><tgroup cols="4"><colspec colnum="1" colname="col1"/><colspec colnum="2" colname="col2"/><colspec colnum="3" colname="col3"/><colspec colnum="4" colname="col4"/><thead><row rowsep="1" valign="top"><entry>Generic Name</entry><entry>Trade Name</entry><entry>Adult Dose</entry><entry>Comments</entry></row></thead><tbody><row valign="top"><entry namest="col1" nameend="col4">Propionic acids</entry></row><row valign="top"><entry>Fenoprofen</entry><entry>Naflon</entry><entry>200 mg every 4&ndash;6 h as needed</entry><entry>Maximum: 3.2 g/d; do not crush tablets</entry></row><row valign="top"><entry>Flurbiprofen</entry><entry>Ocufen</entry><entry>50&ndash;100 mg 2&ndash;3 times daily</entry><entry>Maximum: 300 mg/d; maximum single dose100 mg; do not crush tablets</entry></row><row valign="top"><entry>Ibuprofen</entry><entry>Motrin<ce:br/>Advil</entry><entry>200&ndash;400 mg every 4&ndash;6 h<ce:br/>Maximum: 3.2 g/d</entry><entry>Available OTC; available in tablet (regular and chewable), capsule, suspension and infant drops; chewable tablets may contain phenylalanine</entry></row><row valign="top"><entry>Ketoprofen</entry><entry>Oruvail</entry><entry>25&ndash;50 mg every 6&ndash;8 h as needed</entry><entry>Extended-release formulation is not recommended for acute pain; maximum (immediate release) 300 mg/d; maximum (extended release): 200 mg/d</entry></row><row valign="top"><entry>Naproxen sodium</entry><entry>Aleve<ce:br/>Anaprox<ce:br/>Anaprox DS</entry><entry>500 mg initially, then 250 mg every 6&ndash;8 h as needed<ce:br/>OTC label: 200 mg every 8&ndash;12 h as needed</entry><entry>Available OTC; dosage recommendations expressed as naproxen base; maximum (adult): 1250 mg/d (naproxen base); OTC formulation not indicated for age &lt;12 y</entry></row><row valign="top"><entry>Naproxen</entry><entry>Naprosyn<ce:br/>Naprelan</entry><entry>500 mg initially, then 250 mg every 6&ndash;8 h as needed</entry><entry>Available as immediate-release, extended-release and suspension; extended release not recommended for acute pain; do not break, crush, or chew extended-release formulation; maximum (adult): 1250 mg/d</entry></row><row valign="top"><entry>Oxaprozin</entry><entry>Daypro</entry><entry>600&ndash;1200 mg daily</entry><entry>Patients with low body weight should start with 600 mg daily; do not crush tablets</entry></row><row valign="top"><entry namest="col1" nameend="col4">Acetic acids</entry></row><row valign="top"><entry>Diclofenac</entry><entry>Voltaren</entry><entry>50 mg 3 times daily</entry><entry>Available as immediate, extended-release formulation and powder for solution; do not crush or chew tablets; mix powder in 30&ndash;60 mL of water and drink immediately; maximum: 200 mg daily</entry></row><row valign="top"><entry>Diclofenac patch</entry><entry>Flector patch</entry><entry>Apply 1 patch twice daily</entry><entry>Apply patch to most painful area of intact skin; wash hands after applying and after removal; may tape edges of patch if peeling occurs; do not wear while sunbathing; fold used patches before disposal</entry></row><row valign="top"><entry>Etodolac</entry><entry>Lodine</entry><entry>200&ndash;400 mg every 6&ndash;8 h</entry><entry>Maximum: 1000 mg daily (immediate-release) and 1200 mg daily (extended-release); available as immediate- and extended-release formulation; do not crush tablets or break capsules</entry></row><row valign="top"><entry>Sulindac</entry><entry>Clinoril</entry><entry>150&ndash;200 mg twice daily</entry><entry>Maximum: 400 mg daily</entry></row><row valign="top"><entry>Tolmetin</entry><entry>Tolectin</entry><entry>400 mg 3 times daily</entry><entry>Maximum: 1800 mg daily; taking with food decreases bioavailability; do not crush tablets or break capsules</entry></row><row valign="top"><entry>Indomethacin</entry><entry>Indocin</entry><entry>25&ndash;50 mg 2&ndash;3 times daily<ce:br/>Age &ge;15 y: same as adult</entry><entry>Available as immediate- and extended-release capsules and suspension; maximum (adult): 200 mg/d (immediate-release) and 150 mg/d (extended-release); do not crush, break or chew capsules</entry></row><row valign="top"><entry>Ketorolac</entry><entry>Toradol</entry><entry>20 mg, then 10 mg every 4&ndash;6 h as needed<ce:br/>&lt;50 kg: 10 mg, then 10 mg every 4&ndash;6 h as needed</entry><entry>Not to exceed 5 d in duration (injection and oral combined); maximum: 40 mg daily; oral dosing intended to be a continuation of IM/IV therapy; not indicated for minor or chronic pain conditions</entry></row><row valign="top"><entry namest="col1" nameend="col4">Oxicams</entry></row><row valign="top"><entry>Meloxicam</entry><entry>Mobic</entry><entry>7.5&ndash;15 mg once daily</entry><entry>Available as oral suspension</entry></row><row valign="top"><entry>Piroxicam</entry><entry>Feldene</entry><entry>10&ndash;20 mg once daily</entry><entry>Maximum: 20 mg/d; do not break capsules</entry></row><row valign="top"><entry namest="col1" nameend="col4">Naphthylalkanone</entry></row><row valign="top"><entry>Nabumetone</entry><entry>Relafen</entry><entry>1000 mg daily in 1&ndash;2 divided doses</entry><entry>Maximum: 2 g/d; do not crush tablets</entry></row><row valign="top"><entry namest="col1" nameend="col4">Fenamate</entry></row><row valign="top"><entry>Meclofenamate</entry><entry/><entry>50&ndash;100 mg every 4&ndash;6 h as needed<ce:br/>Age &gt;14 y: same as adult</entry><entry>Maximum: 400 mg/d</entry></row><row valign="top"><entry>Mefenamic acid</entry><entry>Ponstel</entry><entry>500 mg, then 250 mg every 4 h as needed<ce:br/>Age &gt;14 y: same as adult</entry><entry>Maximum duration: usually 1 week</entry></row><row valign="top"><entry namest="col1" nameend="col4">COX-2 inhibitor</entry></row><row valign="top"><entry>Celecoxib</entry><entry>Celebrex</entry><entry>200 mg twice daily as needed</entry><entry>Contents of capsule may be sprinkled onto applesauce for administration; poor metabolizers of CYP 2C9 start at half the recommended dose</entry></row></tbody></tgroup></ce:table><ce:table id="tbl5" frame="topbot" colsep="0" rowsep="0"><ce:label>Table 5</ce:label><ce:caption><ce:simple-para>Acetaminophen formulations and dosing</ce:simple-para></ce:caption><ce:source><ce:italic>Data from</ce:italic> Ref.<ce:cross-ref refid="bib19"><ce:sup>19</ce:sup></ce:cross-ref></ce:source><tgroup cols="2"><colspec colnum="1" colname="col1"/><colspec colnum="2" colname="col2"/><tbody><row valign="top"><entry>Formulation</entry><entry>Regular: 80 mg, 160 mg, 325 mg<ce:br/>Extra strength: 500 mg<ce:br/>Extended release: 650 mg<ce:br/>Liquid: 80 mg/0.8 mg, 160 mg/5 mL, 500 mg/15 mL<ce:br/>Rectal suppository: 80 mg, 120 mg, 325 mg, 650 mg</entry></row><row valign="top"><entry>Dosage (adult and adolescent)</entry><entry>325&ndash;650 mg every 4&ndash;6 h as needed<ce:br/>1000 mg 3&ndash;4 times daily<ce:br/>Not to exceed 4 g/d</entry></row><row valign="top"><entry>Comments</entry><entry>80 mg and 160 mg available in chewable, oral disintegrating, and meltaways<ce:br/>Shake suspension well before dispensing<ce:br/>Avoid chronic use in hepatic impairment<ce:br/>Chewable tablets may contain phenylalanine<ce:br/>Avoid or limit alcohol to &lt;3 drinks per day<ce:br/>Avoid other products with acetaminophen</entry></row></tbody></tgroup></ce:table><ce:table id="tbl6" frame="topbot" colsep="0" rowsep="0"><ce:label>Table 6</ce:label><ce:caption><ce:simple-para>Classification of topical analgesics with counterirritant properties<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref></ce:simple-para></ce:caption><ce:source><ce:italic>Data from</ce:italic> Wright E. Musculoskeletal injuries and disorders. In: Berardi R, Ferreri S, Hume A, et&nbsp;al, editors. Handbook of nonprescription drugs, an interactive approach to self-care. 16th edition. Washington, DC: American Pharmacists Association; 2009. p. 95&ndash;113</ce:source><tgroup cols="3"><colspec colnum="1" colname="col1"/><colspec colnum="2" colname="col2"/><colspec colnum="3" colname="col3"/><thead><row rowsep="1" valign="top"><entry>Group Classification</entry><entry>Mechanism</entry><entry>Counterirritant</entry></row></thead><tbody><row valign="top"><entry>I</entry><entry>Rubefacients</entry><entry>Methyl salicylate<ce:br/>Turpentine oil<ce:br/>Ammonia water</entry></row><row valign="top"><entry>II</entry><entry>Cooling sensation</entry><entry>Camphor<ce:br/>Menthol</entry></row><row valign="top"><entry>III</entry><entry>Vasodilation</entry><entry>Histamine dihydrochloride<ce:br/>Methyl nicotinate</entry></row><row valign="top"><entry>IV</entry><entry>Irritation without rubefaction</entry><entry>Capsaicin<ce:br/>Capsicum oleoresin<ce:cross-ref refid="tblfn1"><ce:sup>a</ce:sup></ce:cross-ref></entry></row></tbody></tgroup><ce:table-footnote id="tblfn1"><ce:label>a</ce:label><ce:note-para>Capsaicin is the major ingredient in capsicum oleoresin.</ce:note-para></ce:table-footnote></ce:table><ce:table id="tbl7" frame="topbot" colsep="0" rowsep="0"><ce:label>Table 7</ce:label><ce:caption><ce:simple-para>Topical analgesic agents</ce:simple-para></ce:caption><ce:source><ce:italic>Data from</ce:italic> Ref.<ce:cross-ref refid="bib58"><ce:sup>58</ce:sup></ce:cross-ref></ce:source><tgroup cols="3"><colspec colnum="1" colname="col1"/><colspec colnum="2" colname="col2"/><colspec colnum="3" colname="col3"/><thead><row rowsep="1" valign="top"><entry>Preparation</entry><entry>Product</entry><entry>Ingredients</entry></row></thead><tbody><row valign="top"><entry morerows="5">Menthol preparations</entry><entry>ActivOn Topical Analgesic Ultra Strength Joint and Muscle</entry><entry>Menthol 4.127%</entry></row><row valign="top"><entry>Icy Hot Extra Strength Medicated Patch</entry><entry>Menthol 5%</entry></row><row valign="top"><entry>Ben Gay Ultra Strength Pain Relieving Patch</entry><entry>Menthol 5%</entry></row><row valign="top"><entry>Absorbine Jr. Pain Relieving Liquid</entry><entry>Menthol 1.27%</entry></row><row valign="top"><entry>Aspercreme Heat Pain Relieving Gel</entry><entry>Menthol 10%</entry></row><row valign="top"><entry>Flexall Maximum Strength Relieving Gel</entry><entry>Menthol 16%</entry></row><row valign="top"><entry>Camphor preparations</entry><entry>JointFlex Arthritis Pain Relieving Cream</entry><entry>Camphor 3.1%</entry></row><row valign="top"><entry morerows="3">Capsaicin preparations</entry><entry>Capzasin Arthritis Pain Relief No Mess Applicator</entry><entry>Capsaicin 0.15%</entry></row><row valign="top"><entry>Zostrix Arthritis Pain Relief Cream</entry><entry>Capsaicin 0.025%</entry></row><row valign="top"><entry>Zostrix HP Arthritis Pain Relief Cream</entry><entry>Capsaicin 0.075%</entry></row><row valign="top"><entry>WellPatch Natural Capsaicin Pain Relief Patch</entry><entry>Capsaicin 0.025%</entry></row><row valign="top"><entry morerows="2">Trolamine preparations</entry><entry>Aspercreme Analgesic Creme Rub</entry><entry>Trolamine 10%</entry></row><row valign="top"><entry>Mobisyl Maximal Strength Arthritis Pain Relief Creme</entry><entry>Trolamine 10%</entry></row><row valign="top"><entry>Sportscreme Deep Penetrating Pain Relieving Rub</entry><entry>Trolamine 10%</entry></row><row valign="top"><entry morerows="6">Combination preparations</entry><entry>Tiger Muscle Rub</entry><entry>Methyl salicylate 15%<ce:br/>Menthol 5%<ce:br/>Camphor 3%</entry></row><row valign="top"><entry>ActivOn Topical Analgesic Ultra Strength Backache</entry><entry>Histamine dihydrochloride 0.025%<ce:br/>Menthol 4.127%<ce:br/>Camphor 3.15%</entry></row><row valign="top"><entry>Salonpas Pain Patch</entry><entry>Camphor 1.12%<ce:br/>Menthol 5.7%<ce:br/>Methyl salicylate 6.3%</entry></row><row valign="top"><entry>Icy Hot Extra Strength Pain Relieving Chill Stick</entry><entry>Methyl salicylate 30%<ce:br/>Menthol 10%</entry></row><row valign="top"><entry>Icy Hot Extra Strength Relieving Balm</entry><entry>Methyl salicylate 29%<ce:br/>Menthol 7.6%</entry></row><row valign="top"><entry>Heet Pain Relieving Formula</entry><entry>Camphor 3.6%<ce:br/>Methyl salicylate 18%<ce:br/>Oleoresin capsicum 0.25%</entry></row><row valign="top"><entry>Freeze It Advanced Therapy Pain Relief, Roll On</entry><entry>Camphor 0.2%<ce:br/>Menthol 3.5%</entry></row></tbody></tgroup></ce:table><ce:textbox id="tbox1"><ce:label>Box 1</ce:label><ce:caption><ce:simple-para>General guidelines for the use of topical analgesics</ce:simple-para></ce:caption><ce:textbox-body><ce:sections><ce:para><ce:list><ce:list-item><ce:para>Apply to affected areas of intact skin 3 to 4 times daily</ce:para></ce:list-item><ce:list-item><ce:para>Massage or rub gently into the affected area</ce:para></ce:list-item><ce:list-item><ce:para>Wash thoroughly with soap and water after application</ce:para></ce:list-item><ce:list-item><ce:para>For patch application, clean and dry the affected areas and remove film before application</ce:para></ce:list-item><ce:list-item><ce:para>Consider using gloves, especially for capsaicin application</ce:para></ce:list-item><ce:list-item><ce:para>Capsaicin is contraindicated for those younger than 18 years</ce:para></ce:list-item><ce:list-item><ce:para>Follow directions for each product carefully</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:floats><head><ce:title>Analgesics and Anti-inflammatory Medications in Sports: Use and Abuse</ce:title><ce:author-group><ce:author id="au1"><ce:given-name>Cynthia L.</ce:given-name><ce:surname>Feucht</ce:surname><ce:degrees>PharmD, BCPS</ce:degrees><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref><ce:cross-ref refid="aff2"><ce:sup>b</ce:sup></ce:cross-ref><ce:cross-ref refid="cor1"><ce:sup>&lowast;</ce:sup></ce:cross-ref><ce:e-address type="email">cynthia.feucht@gmail.com</ce:e-address></ce:author><ce:author id="au2"><ce:given-name>Dilip R.</ce:given-name><ce:surname>Patel</ce:surname><ce:degrees>MD, FAAP, FACSM, FAACPDM, FSAM</ce:degrees><ce:cross-ref refid="aff2"><ce:sup>b</ce:sup></ce:cross-ref><ce:cross-ref refid="aff3"><ce:sup>c</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="aff1"><ce:label>a</ce:label><ce:textfn>Department of Pharmacy Practice, Ferris State University, Kalamazoo, MI, USA</ce:textfn></ce:affiliation><ce:affiliation id="aff2"><ce:label>b</ce:label><ce:textfn>MSU/KCMS, 1000 Oakland Drive, Kalamazoo, MI 49008, USA</ce:textfn></ce:affiliation><ce:affiliation id="aff3"><ce:label>c</ce:label><ce:textfn>Department of Pediatrics and Human Development, Michigan State University College of Human Medicine, East Lansing, MI, USA</ce:textfn></ce:affiliation><ce:correspondence id="cor1"><ce:label>&lowast;</ce:label><ce:text>Corresponding author. MSU/KCMS, 1000 Oakland Drive, Kalamazoo, MI 49008.</ce:text></ce:correspondence></ce:author-group><ce:abstract class="teaser"><ce:abstract-sec><ce:simple-para view="extended">Both acute and overuse musculoskeletal injuries are common in adolescent athletes. Pharmacologic agents including nonsteroidal anti-inflammatory drugs, acetaminophen, and topical over-the-counter agents have been shown to be effective in controlling pain, but data regarding their efficacy in expediting healing and time to recovery continue to be debated. Studies indicate that adolescents consume analgesic agents on their own and may be unaware of their potential toxicities. Data also indicate that adolescent athletes use medications in hopes of alleviating pain and allowing continuation of sports without adequate time for healing. This article reviews the mechanisms, toxicity, drug interactions, efficacy, and abuse potential of commonly used analgesic and anti-inflammatory drugs.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords xml:lang="en"><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Musculoskeletal injury</ce:text></ce:keyword><ce:keyword><ce:text>Nonsteroidal anti-inflammatory drugs</ce:text></ce:keyword><ce:keyword><ce:text>Acetaminophen</ce:text></ce:keyword><ce:keyword><ce:text>Topical analgesics</ce:text></ce:keyword><ce:keyword><ce:text>Sports</ce:text></ce:keyword></ce:keywords></head><body><ce:sections><ce:para>Musculoskeletal injuries account for most sports-related injuries.<ce:cross-ref refid="bib1"><ce:sup>1</ce:sup></ce:cross-ref> Overuse musculoskeletal injuries account for more than half of all sport-related injuries in adolescents and young adults. Overuse injuries can result in chronic or intermittent symptoms depending on the athlete&apos;s level of activity. Acute muscle injuries (strains, contusions, and lacerations) can lead to significant structural or functional damage to the muscle.<ce:cross-refs refid="bib1 bib2 bib3 bib4 bib5 bib6 bib7 bib8 bib9 bib10 bib11"><ce:sup>1&ndash;11</ce:sup></ce:cross-refs> Delayed-onset muscle soreness (DOMS) (exercise-induced muscle damage [EIMD]), typically associated with new or unaccustomed exercise, often results from intense eccentric muscle activity and manifests with pain, discomfort, and decreased performance 24 to 48 hours after exercise.<ce:cross-refs refid="bib1 bib4"><ce:sup>1,4</ce:sup></ce:cross-refs></ce:para><ce:para>Nonpharmacological approaches are often considered as first-line treatment for musculoskeletal injuries and may include relative rest, ice, compression, and elevation.<ce:cross-ref refid="bib3"><ce:sup>3</ce:sup></ce:cross-ref> Moderate to severe injuries to the athlete may result in several weeks of an inability to train or compete. Even after resuming the physical activity or sport, the athlete may continue to experience difficulties with muscle weakness and decreased flexibility.<ce:cross-ref refid="bib1"><ce:sup>1</ce:sup></ce:cross-ref> As a result, treatment is often sought to alleviate pain, restore function, and allow the athlete to resume activities more quickly. Treatment options include analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and topical over-the-counter (OTC) preparations. These classes of drugs are reviewed in this article, including their mechanisms of action, side effects, and efficacy in treating pain and inflammation associated with acute and overuse musculoskeletal injuries.</ce:para><ce:section id="sec2"><ce:section-title>Mechanism of action</ce:section-title><ce:para>Arachidonic acid is released from cellular membranes as a result of tissue injury. Arachidonic acid is broken down by cyclooxygenase (COX) to produce prostaglandins and thromboxane A<ce:inf>2,</ce:inf> and by lipoxygenase (LOX) enzymes to produce leukotrienes. Prostaglandins are localized hormones that, once released within the intracellular space, can produce fever, inflammation, and pain.<ce:cross-ref refid="bib12"><ce:sup>12</ce:sup></ce:cross-ref> Thromboxanes are released in response to tissue injury and are responsible for producing platelet aggregation and clot formation, and for regulation of vascular tone.<ce:cross-ref refid="bib12"><ce:sup>12</ce:sup></ce:cross-ref> Pain relief and decreased inflammation occur from the blockade of COX enzymes, thereby inhibiting prostaglandin E<ce:inf>2</ce:inf> and prostacyclin (PGI<ce:inf>2</ce:inf>) formation (<ce:cross-ref refid="fig1">Fig.&nbsp;1</ce:cross-ref><ce:float-anchor refid="fig1"/>).<ce:cross-refs refid="bib12 bib13"><ce:sup>12,13</ce:sup></ce:cross-refs></ce:para><ce:para>Two forms of COX enzymes are cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). COX-1 is expressed in most normal tissues and cells, and is the predominant form within gastric epithelial cells.<ce:cross-refs refid="bib12 bib14"><ce:sup>12,14</ce:sup></ce:cross-refs> Prostaglandin production within the gastrointestinal tract protects the gastrointestinal mucosa from gastric acidity. COX-2 is expressed when tissue damage occurs, and its release is induced by cytokines and inflammatory mediators during inflammation.<ce:cross-refs refid="bib12 bib14"><ce:sup>12,14</ce:sup></ce:cross-refs></ce:para><ce:para>NSAIDs are a heterogeneous class of medications that are chemically unrelated but known to have similar therapeutic effects, including antipyretic, analgesic, and anti-inflammatory activity. Their primary therapeutic effect is due to inhibition of prostaglandin synthesis by inhibiting COX-2 activity, and a correlation exists between COX-2 inhibition and anti-inflammatory activity.<ce:cross-ref refid="bib15"><ce:sup>15</ce:sup></ce:cross-ref> Bradykinin and cytokines (ie, tumor necrosis factor-&alpha; [TNF-&alpha;] and interleukin-1 [IL-1]) are thought to be responsible for inducing pain with inflammation and releasing prostaglandins that enhance pain sensitivity.<ce:cross-ref refid="bib16"><ce:sup>16</ce:sup></ce:cross-ref> Other mediators, such as neuropeptides (ie, substance P) are also involved in inducing pain. The gastrointestinal adverse effects of NSAIDs are predominantly, but not exclusively, due to inhibition of COX-1 enzyme (<ce:cross-ref refid="fig2">Fig.&nbsp;2</ce:cross-ref><ce:float-anchor refid="fig2"/>). NSAIDs are considered competitive, reversible inhibitors of COX enzymes (unlike aspirin, which is considered an irreversible inhibitor of COX enzymes) and do not affect the LOX pathway.<ce:cross-ref refid="bib17"><ce:sup>17</ce:sup></ce:cross-ref></ce:para></ce:section><ce:section id="sec3"><ce:section-title>Salicylated NSAIDs</ce:section-title><ce:para>Derivatives of salicylic acid include aspirin (acetylsalicylic acid), diflunisal (difluorophenyl derivative), salsalate, magnesium salicylate, and choline magnesium salicylate (<ce:cross-ref refid="tbl1">Tables 1</ce:cross-ref> and <ce:cross-ref refid="tbl2">2</ce:cross-ref><ce:float-anchor refid="tbl1"/><ce:float-anchor refid="tbl2"/>). Aspirin continues to be the most widely used drug and is the standard to which other NSAIDs are compared.<ce:cross-ref refid="bib18"><ce:sup>18</ce:sup></ce:cross-ref> Due to its widespread availability, aspirin&apos;s potential for toxicity often goes underrecognized, and it continues to be a cause of fatal poisonings in children.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref></ce:para><ce:para>Salicylates are rapidly absorbed from the gastrointestinal tract, are widely distributed throughout the body, and are highly protein bound (especially albumin).<ce:cross-ref refid="bib16"><ce:sup>16</ce:sup></ce:cross-ref> Due to their high protein binding, salicylates may compete for binding with other compounds, including thyroxine, penicillin, phenytoin, bilirubin, uric acid, and other NSAIDs such as naproxen.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref> Salicylates are metabolized in the liver and excreted by the kidneys, with free salicylate excretion dependent on urinary pH and salicylate dose.<ce:cross-ref refid="bib16"><ce:sup>16</ce:sup></ce:cross-ref></ce:para><ce:para>Gastrointestinal adverse effects are common with salicylates and may include dyspepsia, nausea, vomiting and, more seriously, gastric ulceration, gastrointestinal hemorrhage, and erosive gastritis.<ce:cross-refs refid="bib14 bib16"><ce:sup>14,16</ce:sup></ce:cross-refs> Aspirin irreversibly inhibits platelet aggregation and leads to a prolongation in the bleeding time. Gastrointestinal and platelet effects are less likely to occur with nonacetylated salicylates (ie, salsalate, magnesium salicylate, and so forth) because they cannot acetylate COX.<ce:cross-ref refid="bib16"><ce:sup>16</ce:sup></ce:cross-ref> Owing to aspirin&apos;s effect on platelet aggregation, it should be avoided in patients with hepatic impairment, hypoprothrombinemia, vitamin K deficiency, hemophilia, and within 1 week of a surgical procedure.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref></ce:para><ce:para>Salicylates have been shown to have a dose-dependent effect on uric acid excretion, and in elevated doses can result in pulmonary edema, hepatotoxicity, and hyperglycemia.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref> Hypersensitivity to salicylates can result in hives, flushing, bronchoconstriction, angioedema, low blood pressure, and shock.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref> Hypersensitivity is thought to be due to COX inhibition, and cross-sensitivity occurs with other agents in the class as well as with nonsalicylated NSAIDs.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref> Patients with asthma, nasal polyps, and sensitivity to tartrazine dyes are at an increased risk for salicylate sensitivity.<ce:cross-ref refid="bib19"><ce:sup>19</ce:sup></ce:cross-ref> In general, salicylates are avoided during pregnancy, especially the third trimester, due to an increased risk for perinatal death, anemia, antepartum and postpartum hemorrhage, prolonged gestation, and premature closure of the ductus arteriosus.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref></ce:para><ce:para>Drug interactions can occur from salicylates displacing other agents from plasma-binding proteins. Dosages of NSAIDs, sulfonylureas, and methotrexate may need to be adjusted to prevent toxicity due to displacement. NSAIDs given concurrently with corticosteroids and warfarin may increase the risk for bleeding. NSAIDs should not be given concomitantly with the following herbals due to their anticoagulant or antiplatelet activity and increased risk for bleeding: danshen, dong quai, evening primrose, feverfew, garlic, ginger, ginkgo, red clover, horse chestnut, green tea, policosanol, and willowbark.<ce:cross-refs refid="bib19 bib20"><ce:sup>19,20</ce:sup></ce:cross-refs> In addition, NSAIDs decrease the effectiveness of angiotensin-converting enzyme (ACE) inhibitors because of the blockade of renal prostaglandin production.</ce:para><ce:para>Salicylates have fallen out of favor for use in adolescents and young adults because of their association with Reye syndrome. Reye syndrome is characterized by toxic hepatitis and has been associated with encephalopathy, prolonged prothrombin time, fatty infiltration of the liver, and intracranial hypertension in advanced stages.<ce:cross-ref refid="bib21"><ce:sup>21</ce:sup></ce:cross-ref> Aspirin and other salicylates are contraindicated in children and young adults younger than 20 years who have a fever associated with a viral illness.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref></ce:para></ce:section><ce:section id="sec4"><ce:section-title>Nonsalicylated NSAIDs</ce:section-title><ce:para>Various classes of nonsalicylated NSAIDs (<ce:cross-ref refid="tbl3">Tables 3</ce:cross-ref> and <ce:cross-ref refid="tbl4">4</ce:cross-ref><ce:float-anchor refid="tbl3"/><ce:float-anchor refid="tbl4"/>) are among the most widely used drugs, with yearly sales in the United States for OTC drugs estimated at $30 billion.<ce:cross-refs refid="bib13 bib22"><ce:sup>13,22</ce:sup></ce:cross-refs> Nonsalicylated NSAIDs are considered effective for mild to moderate pain, and have been used for a variety of musculoskeletal disorders including osteoarthritis, rheumatoid arthritis, and sports-related injuries. The choice of a particular nonsalicylated NSAID depends on its onset of action, tolerability, cost, and insurance coverage. An agent with a short onset of action, minimal adverse effects, low cost, and wide acceptability would make for an ideal nonsalicylated NSAID.</ce:para><ce:para>As a class, nonsalicylated NSAIDs are usually well absorbed and highly bound to plasma proteins, and are excreted via either glomerular filtration or tubular secretion.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref> These agents accumulate at sites of inflammation, and most exhibit nonselectivity for COX-1 and COX-2 enzymes. The last decade has seen the emergence of COX-2 selective inhibitors designed to minimize gastrointestinal effects that occur due to COX-1 inhibition. Other older nonsalicylated NSAIDs have also been found to have COX-2 selectivity similar to the currently available celecoxib, based on whole blood assays.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref> Most studies on nonsalicylated NSAIDs are done in adults; however, some findings are of relevance to the adolescent age group.</ce:para></ce:section><ce:section id="sec5"><ce:section-title>Side effects of nonsalicylated NSAIDs</ce:section-title><ce:section id="sec5.1"><ce:section-title>Gastrointestinal</ce:section-title><ce:para>Gastrointestinal adverse effects are common with nonsalicylated NSAIDs and are often the leading reason for their discontinuation. The gastrointestinal toxicity is often dose dependent and associated with chronic use.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref> Dyspeptic symptoms are frequently experienced by patients and may include anorexia, epigastric pain, nausea, bloating, and heartburn. These symptoms have been associated with both selective and nonselective nonsalicylated NSAIDs.<ce:cross-refs refid="bib13 bib23"><ce:sup>13,23</ce:sup></ce:cross-refs> Gastrointestinal toxicity may be related to prostaglandin inhibition, which is important for enhancing mucosal blood flow, mucus and bicarbonate production, and inhibition of acid production. Nonsalicylated NSAIDs also may contribute to gastrointestinal toxicity from local irritation to the gastric mucosa. More serious complications include gastric and duodenal ulcers, which may occur in up to 15% to 30% of regular nonsalicylated NSAID users.<ce:cross-refs refid="bib24 bib25"><ce:sup>24,25</ce:sup></ce:cross-refs> Complications from ulcers include bleeding, perforation, and obstruction. Patients may present with a serious gastrointestinal event but have had no symptoms before presentation.<ce:cross-ref refid="bib13"><ce:sup>13</ce:sup></ce:cross-ref> Factors that may increase the risk for gastrointestinal complications include the presence of <ce:italic>Helicobacter pylori</ce:italic>, advanced age, concomitant use of aspirin, anticoagulants, or corticosteroids, and duration of NSAID use (greatest within the first month).<ce:cross-refs refid="bib13 bib26"><ce:sup>13,26</ce:sup></ce:cross-refs> Lifestyle factors such as smoking and alcohol use also contribute to an increased risk for side effects, but are not independent risk factors.<ce:cross-refs refid="bib13 bib26"><ce:sup>13,26</ce:sup></ce:cross-refs> For those patients at risk, a proton pump inhibitor (PPI) has been shown to be effective at reducing the frequency and severity of upper gastrointestinal symptoms.<ce:cross-refs refid="bib13 bib27"><ce:sup>13,27</ce:sup></ce:cross-refs></ce:para><ce:para>COX-2 inhibitors were developed with the aim of reducing gastrointestinal complications associated with nonselective nonsalicylated NSAIDs. COX-2 inhibitors do not inhibit the COX-1 enzyme, which is responsible for prostaglandin production in the gastrointestinal mucosa, and therefore should have less risk for gastrointestinal toxicity. The benefit of COX-2 inhibitors with regard to less gastrointestinal toxicity remains controversial. In patients with gastrointestinal disease or risk factors for gastrointestinal complications, risk versus benefit should be assessed, and if nonsalicylated NSAIDs are used, the lowest dose for the shortest time period should be considered.<ce:cross-refs refid="bib24 bib28"><ce:sup>24,28</ce:sup></ce:cross-refs></ce:para></ce:section><ce:section id="sec5.2"><ce:section-title>Hepatotoxicity</ce:section-title><ce:para>Hepatotoxicity from NSAID use appears to be rare, with estimates between 3 and 23 cases per 10,000 patient years.<ce:cross-refs refid="bib29 bib30"><ce:sup>29,30</ce:sup></ce:cross-refs> Two older agents (benoxaprofen and bromfenac) have been withdrawn in the United States due to reports of serious hepatotoxicity.<ce:cross-ref refid="bib13"><ce:sup>13</ce:sup></ce:cross-ref> Rostom and colleagues,<ce:cross-ref refid="bib31"><ce:sup>31</ce:sup></ce:cross-ref> in a systematic review, found the rate of hospitalization due to nonsalicylated NSAID-related hepatotoxicity to be 2.7 per 100,000 patients and the rate of death to be 1.9 per 100,000 patients.</ce:para><ce:para>A recent case report by Bennett and colleagues<ce:cross-ref refid="bib29"><ce:sup>29</ce:sup></ce:cross-ref> details a 16-year-old who was previously healthy and found to be taking ibuprofen for 6 weeks before presentation. The first 2 weeks of ibuprofen use was scheduled dosing and the subsequent 4 weeks was sporadic use. The adolescent presented with dark-colored urine, jaundice, and pruritus. Laboratory results were significant for an elevated bilirubin and minimal elevation in liver enzymes.<ce:cross-ref refid="bib29"><ce:sup>29</ce:sup></ce:cross-ref> The results of a liver biopsy revealed intrahepatic and canalicular cholestasis.<ce:cross-ref refid="bib29"><ce:sup>29</ce:sup></ce:cross-ref> Histology was suggestive of drug-induced hepatotoxicity.<ce:cross-ref refid="bib29"><ce:sup>29</ce:sup></ce:cross-ref> Over the following 4 months, the patient&apos;s symptoms resolved and laboratory values returned to normal.</ce:para><ce:para>Liver dysfunction related to nonsalicylated NSAIDs is rare in otherwise healthy adolescents, but should be considered in a patient with recent nonsalicylated NSAID use and presenting with cholestasis.<ce:cross-ref refid="bib29"><ce:sup>29</ce:sup></ce:cross-ref> Thorough medication histories are important in determining the cause and effect. Despite the potential for hepatotoxicity, current data do not support routine monitoring of liver enzymes in individuals receiving nonsalicylated NSAIDs.</ce:para></ce:section><ce:section id="sec5.3"><ce:section-title>Renal Toxicity</ce:section-title><ce:para>Renal insufficiency is well known with nonsalicylated NSAID use and is likely the result of inhibition of renal prostaglandins. Renal insufficiency is estimated to occur in approximately 1% to 5% of patients, and is usually reversible on discontinuation of the NSAID.<ce:cross-refs refid="bib13 bib32"><ce:sup>13,32</ce:sup></ce:cross-refs> Renal prostaglandins serve an important role in maintaining renal circulation, including vasodilation, renin secretion, and sodium and water excretion.<ce:cross-ref refid="bib13"><ce:sup>13</ce:sup></ce:cross-ref> The disruption in balance between vasoconstriction and vasodilation within the kidneys may predispose a patient to renal failure. Those at the greatest risk for renal toxicity associated with nonsalicylated NSAIDs include patients with heart failure, cirrhosis, chronic kidney disease, and hypovolemic states.<ce:cross-refs refid="bib13 bib14"><ce:sup>13,14</ce:sup></ce:cross-refs> Renal toxicity is characterized by elevated serum creatinine, sodium and water retention, hyperkalemia, proteinuria, interstitial nephritis, papillary necrosis, acute renal failure, acute glomerulitis, vasculitis, acute tubular necrosis, and papillary necrosis.<ce:cross-refs refid="bib13 bib33 bib34"><ce:sup>13,33,34</ce:sup></ce:cross-refs> In patients at risk for renal toxicity, the risk versus benefit in using a nonsalicylated NSAID should be carefully considered and, if at all possible, NSAIDs, including COX-2 inhibitors, should be avoided.</ce:para><ce:para>There have been several case reports of renal toxicity in adolescents with nonsalicylated NSAID use. Nakahura and colleagues<ce:cross-ref refid="bib35"><ce:sup>35</ce:sup></ce:cross-ref> discuss 5 adolescents (13&ndash;19 years old) who developed renal toxicity with the use of nonsalicylated NSAIDs. The first case was a 16-year-old girl who took ibuprofen intermittently over 9 months. Kidney biopsy results were consistent with interstitial nephritis and the patient was treated with corticosteroids. At 1 year she was asymptomatic with a decrease in serum creatinine; however, 2 years later her serum creatinine had risen and results of a repeat kidney biopsy revealed chronic interstitial fibrosis.<ce:cross-ref refid="bib35"><ce:sup>35</ce:sup></ce:cross-ref> Case 3 in this report describes a 15-year-old girl who used ibuprofen every other day for 6 months. The patient was found to have proteinuria, and results of renal ultrasonography were reported normal. The patient discontinued the nonsalicylated NSAID and was asymptomatic after 1 month.<ce:cross-ref refid="bib35"><ce:sup>35</ce:sup></ce:cross-ref> The other 3 cases describe adolescents who used naprosyn (1 week before hospitalization), ibuprofen (daily use for several weeks), and ketorolac (intermittently for 4 months), who all developed an increase in serum creatinine and were found to have urine eosinophilia indicative of nonsalicylated NSAID-associated nephrotoxicity.<ce:cross-ref refid="bib35"><ce:sup>35</ce:sup></ce:cross-ref> In 2 of the cases nephrotoxicity resolved, and the other case reported resolution of symptoms at 1 month but continued elevation in serum creatinine.</ce:para><ce:para>These case reports illustrate that nonsalicylated NSAID nephrotoxicity can occur in healthy adolescents. Given the fact that several nonsalicylated NSAIDs are available as OTC preparations, adolescents should be aware of their potential adverse effects. It is important to use the lowest dose of the nonsalicylated NSAID for the shortest time period necessary, and to maintain adequate hydration while on nonsalicylated NSAIDs.</ce:para></ce:section><ce:section id="sec5.4"><ce:section-title>Cardiovascular Toxicity</ce:section-title><ce:para>Cardiovascular toxicity related to nonsalicylated NSAID use is generally not of concern in otherwise healthy adolescents. Cardiovascular toxicity came to light with the emergence of the selective COX-2 inhibitors. It has been theorized that the disruption in the balance between prostacyclin and thromboxane formation by selective COX-2 inhibitors may increase this risk. The selective COX-2 inhibitors, via their inhibition of prostacyclin formation, favor increased thromboxane formation and subsequent platelet aggregation.</ce:para><ce:para>Current data suggest that selective nonsalicylated NSAIDs may increase cardiovascular risk, but data are conflicting.<ce:cross-refs refid="bib24 bib36 bib37 bib38"><ce:sup>24,36&ndash;38</ce:sup></ce:cross-refs> Heterogeneity of the studies including patient selection, duration of study, agents used, study design, and cardiovascular risk at baseline makes it challenging to summarize the cardiovascular risks associated with nonsalicylated NSAIDs. Rofecoxib was voluntarily withdrawn from the United States market in September 2004, and the Food and Drug Administration (FDA) requested Pfizer to voluntarily remove valdecoxib from the market in April 2005 because of cardiovascular risks.<ce:cross-ref refid="bib39"><ce:sup>39</ce:sup></ce:cross-ref> In addition, in 2005 the FDA requested the makers of prescription and OTC nonsalicylated NSAIDs to include a boxed warning highlighting the increased risk for cardiovascular events as well as gastrointestinal toxicity, including the risk for life-threatening gastrointestinal bleeding.<ce:cross-ref refid="bib39"><ce:sup>39</ce:sup></ce:cross-ref></ce:para></ce:section><ce:section id="sec5.5"><ce:section-title>Drug Interactions</ce:section-title><ce:para>Drug interactions are similar to those already described for salicylated NSAIDs as well as the following additional drug interactions. Nonselective nonsalicylated NSAIDs may decrease the effectiveness of aspirin if given concomitantly due to blockade of the platelet COX-1 site.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref> It is recommended that the nonsalicylated NSAIDs be given at least 2 hours after the dose of aspirin to achieve irreversible platelet inhibition by aspirin.<ce:cross-ref refid="bib13"><ce:sup>13</ce:sup></ce:cross-ref> Nonsalicylated NSAIDs may also decrease the effectiveness of thiazide and loop diuretics through blockade of renal prostaglandins.<ce:cross-ref refid="bib40"><ce:sup>40</ce:sup></ce:cross-ref> In addition, nonsalicylated NSAIDs can reduce renal clearance of lithium, resulting in elevated lithium plasma levels, and the efficacy of nonsalicylated NSAIDs can be reduced with cholestyramine and colestipol due to blockade of absorption.<ce:cross-ref refid="bib40"><ce:sup>40</ce:sup></ce:cross-ref> Drug interactions can occur with mefenamic acid, celecoxib, meloxicam, ibuprofen, and flurbiprofen due to their metabolism via cytochrome P450 isoenzymes. With a wide variety of drug interactions, each patient&apos;s medication profile should be reviewed, including prescription, OTC, and herbal products, to evaluate for drug-drug interactions before initiating an nonsalicylated NSAID.</ce:para></ce:section></ce:section><ce:section id="sec6"><ce:section-title>Efficacy of NSAIDs in musculoskeletal injuries</ce:section-title><ce:para>NSAIDs have been purported to help in decreasing pain and inflammation, restore musculoskeletal function, decrease time to healing, and allow faster return to previous activity level. The benefit of using NSAIDs in the prevention of myositis ossificans traumatica following deep muscle contusions remains controversial. Concern has been raised that by inhibiting the inflammatory response, NSAIDs may slow phagocytic function and time for muscle regeneration and healing. Animal studies have been conflicting as to the effects of NSAIDs in the musculoskeletal model. Human studies have not always shown a consistent benefit of NSAIDs in treating musculoskeletal injuries. Studies have been limited at times by small sample sizes, lack of placebo group, subjective assessment, differing patient populations, and lack of control for confounding factors.</ce:para><ce:para>A recent review by Mehallo and colleagues<ce:cross-ref refid="bib3"><ce:sup>3</ce:sup></ce:cross-ref> summarized data regarding use of NSAIDs for acute ligament and muscle injuries. Rat models for ligament sprains have shown that piroxicam strengthens the medial collateral ligament of the knee at 14 days versus celecoxib, which was found to weaken the medial collateral ligament at 14 days compared with placebo. Other animal studies have not found any benefit with selective and nonselective NSAIDs versus placebo.<ce:cross-ref refid="bib3"><ce:sup>3</ce:sup></ce:cross-ref> Human studies have provided evidence for a more consistent benefit of NSAIDs in ligament sprains. A variety of NSAIDs have been shown to decrease pain and inflammation associated with acute ankle sprains.<ce:cross-ref refid="bib3"><ce:sup>3</ce:sup></ce:cross-ref> Several studies have documented the efficacy of NSAIDs in decreasing pain, increasing functional ability, and allowing for a more rapid return to training.<ce:cross-ref refid="bib3"><ce:sup>3</ce:sup></ce:cross-ref> Although NSAIDs have been shown to be effective for treating the pain associated with injured ligaments, their efficacy in improving joint stability remains unknown.<ce:cross-ref refid="bib3"><ce:sup>3</ce:sup></ce:cross-ref> In 2 animal model studies, piroxicam was shown to improve contractile force and greater maximal failure force early post injury, but also slowed deposition of collagen and regeneration of muscle tissue.<ce:cross-ref refid="bib3"><ce:sup>3</ce:sup></ce:cross-ref> Studies examining NSAIDs in human muscle strains are limited. One trial evaluated meclofenamate and diclofenac versus placebo along with physiotherapy in treating acute hamstring injuries, and found no differences among the groups with respect to pain, swelling, and isokinetic muscle performance.<ce:cross-ref refid="bib3"><ce:sup>3</ce:sup></ce:cross-ref></ce:para><ce:para>Howatson and van Someren<ce:cross-ref refid="bib5"><ce:sup>5</ce:sup></ce:cross-ref> reviewed the use of NSAIDs in the treatment and prevention of DOMS. In one study, ketoprofen used prophylactically was found to decrease muscle soreness and enhance muscle function, while another study evaluated ibuprofen before and after exercise and demonstrated a decrease in muscle damage. In contrast, a study evaluated ibuprofen 45 minutes before downhill running and scheduled dosing for 3 days after the activity, and found no effect on muscle soreness or strength.<ce:cross-ref refid="bib5"><ce:sup>5</ce:sup></ce:cross-ref> Additional studies with oxaprozin and ibuprofen with acetaminophen post exercise failed to provide benefit.<ce:cross-ref refid="bib5"><ce:sup>5</ce:sup></ce:cross-ref> NSAIDs were found to attenuate loss of muscle strength and muscle soreness in 2 studies post exercise and in one study failed to provide evidence of benefit compared with placebo after elbow flexor eccentric muscle injury.<ce:cross-ref refid="bib3"><ce:sup>3</ce:sup></ce:cross-ref> Conflicting evidence to support the use of NSAIDs in DOMS may be the result of differences in study methodology, patient selection, and study limitations. NSAIDs may provide benefit in decreasing muscle soreness and improving short-term muscle recovery.<ce:cross-refs refid="bib3 bib41"><ce:sup>3,41</ce:sup></ce:cross-refs> Given the potential ability of NSAIDs to impair muscle healing, risk versus benefit should be considered and, if used, a short course of 3 to 7 days should be considered.<ce:cross-ref refid="bib3"><ce:sup>3</ce:sup></ce:cross-ref></ce:para></ce:section><ce:section id="sec7"><ce:section-title>Topical NSAIDs</ce:section-title><ce:para>In addition to oral NSAIDs, topical formulations of NSAIDs have been used for treating musculoskeletal injuries. A systematic review conducted by Moore and colleagues<ce:cross-ref refid="bib42"><ce:sup>42</ce:sup></ce:cross-ref> evaluated 37 placebo-controlled trials of topical NSAIDs in the treatment of acute soft tissue injury, sprains, strains, or trauma. Twenty-seven of the trials demonstrated a significant benefit of the topical NSAID over placebo.<ce:cross-ref refid="bib42"><ce:sup>42</ce:sup></ce:cross-ref> The pooled relative benefit for all trials was 1.7 (95% confidence interval [CI]: 1.5&ndash;1.9).<ce:cross-ref refid="bib42"><ce:sup>42</ce:sup></ce:cross-ref> For topical NSAIDs evaluated in 3 or more studies, pooling of data for the individual agents showed ketoprofen, felbinac, ibuprofen, and piroxicam to be superior to placebo.<ce:cross-ref refid="bib42"><ce:sup>42</ce:sup></ce:cross-ref> Local skin reactions were reported in 3% or fewer, systemic adverse effects in fewer than 1%, and discontinuation due to adverse effects in 0.6% or fewer, with no significant difference noted between active treatment and placebo groups.<ce:cross-ref refid="bib42"><ce:sup>42</ce:sup></ce:cross-ref> The authors note that due to the small sample size of most of the trials, publication bias may have influenced the results of the systematic review.</ce:para><ce:para>Diclofenac gel and topical patch were the first topical NSAIDs approved in 2007 in the United States by the FDA. Diclofenac gel (Voltaren gel) is currently approved for treatment of osteoarthritis and diclofenac topical patch (Flector patch) for the treatment of acute minor sprains, strains, and contusions.<ce:cross-ref refid="bib19"><ce:sup>19</ce:sup></ce:cross-ref> When applied to the skin, diclofenac accumulates under the application site, leading to a tissue reservoir for localized effects.<ce:cross-ref refid="bib43"><ce:sup>43</ce:sup></ce:cross-ref> With its topical application, systemic plasma concentrations are in the range of 1 to 3 ng/mL and relative systemic bioavailability compared with oral administration is approximately 1%.<ce:cross-ref refid="bib43"><ce:sup>43</ce:sup></ce:cross-ref> The diclofenac patch is relatively safe, with skin reactions as the most common adverse event.<ce:cross-ref refid="bib43"><ce:sup>43</ce:sup></ce:cross-ref> Thus, the risk for systemic adverse effects is minimal due to low plasma concentrations.</ce:para><ce:para>A randomized, double-blind, placebo-controlled trial using topical diclofenac in ankle sprains found it to provide a greater reduction in pain on rest and movement from day 2 and faster joint swelling reduction from day 3.<ce:cross-ref refid="bib44"><ce:sup>44</ce:sup></ce:cross-ref> Five percent of the patients in the placebo group discontinued treatment due to lack of efficacy compared with none in the topical diclofenac group.<ce:cross-ref refid="bib44"><ce:sup>44</ce:sup></ce:cross-ref> Another randomized, double-blind, placebo-controlled study compared topical diclofenac to placebo in patients with traumatic blunt soft tissue injury.<ce:cross-ref refid="bib44"><ce:sup>44</ce:sup></ce:cross-ref> Tenderness at the center of the injured area was produced by pressure applied from calibrated calipers. The primary end point was the area under the curve (AUC) for tenderness over the first 3 days of treatment.<ce:cross-ref refid="bib44"><ce:sup>44</ce:sup></ce:cross-ref> The patch was found to be significantly more effective than placebo for the primary end point (<ce:italic>P</ce:italic>&lt;.0001).<ce:cross-ref refid="bib44"><ce:sup>44</ce:sup></ce:cross-ref> Topical diclofenac also produced a greater pain intensity reduction at rest and with activity.<ce:cross-ref refid="bib44"><ce:sup>44</ce:sup></ce:cross-ref> There were no significant differences between the groups with respect to adverse events, and topical diclofenac was well tolerated.<ce:cross-ref refid="bib44"><ce:sup>44</ce:sup></ce:cross-ref> Additional single-blinded or nonrandomized trials have assessed the topical diclofenac patch in acute injuries and have found it to be superior to placebo in relieving pain.<ce:cross-ref refid="bib44"><ce:sup>44</ce:sup></ce:cross-ref></ce:para><ce:para>Studies support the use of topical diclofenac in alleviating pain related to acute injuries, but its ability to improve muscle recovery and allow participants to return to activity more quickly remains to be appropriately evaluated. Topical diclofenac, because of its low systemic bioavailability, may be beneficial in those patients who are at risk for gastrointestinal or cardiovascular toxicity from oral NSAIDs.</ce:para><ce:section id="sec7.1"><ce:section-title>Acetaminophen</ce:section-title><ce:para>Acetaminophen (Tylenol) was initially used in 1893 but did not gain wide acceptance until 1949.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref> Acetaminophen is the active metabolite of phenacetin, which was widely used until the 1980s when it was withdrawn from the market due to its association with analgesic-abuse nephropathy and hemolytic anemia.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref> Acetaminophen, along with NSAIDs, has largely replaced aspirin as the analgesic of choice in children, adolescents, and young adults, because of aspirin&apos;s association with Reye syndrome. Acetaminophen is known to have analgesic and antipyretic activity similar to aspirin; however, acetaminophen has poor anti-inflammatory effects. At typical doses of 1000 mg, acetaminophen has been shown in whole blood assays of healthy volunteers to inhibit only approximately 50% of COX-1 and COX-2 enzymes.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref> Acetaminophen has good bioavailability and is evenly distributed throughout most body fluids.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref> Protein binding of acetaminophen is variable, and it undergoes extensive hepatic metabolism with glucuronidation and sulfation to form inactive metabolites that are excreted by the kidneys.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref> A small percentage (about 5%&ndash;15%) of acetaminophen is metabolized to <ce:italic>N</ce:italic>-acetyl-<ce:italic>p</ce:italic>-benzoquinoneimine (NAPQI), which normally reacts with glutathione sulfhydryl groups, is further metabolized, and then excreted.<ce:cross-ref refid="bib45"><ce:sup>45</ce:sup></ce:cross-ref> When excessive amounts of acetaminophen are consumed, conjugation pathways become saturated and larger amounts of acetaminophen are converted to NAPQI.<ce:cross-refs refid="bib14 bib45"><ce:sup>14,45</ce:sup></ce:cross-refs> With the shift to NAPQI, glutathione stores become depleted and the excessive NAPQI can lead to hepatotoxicity.<ce:cross-refs refid="bib14 bib45"><ce:sup>14,45</ce:sup></ce:cross-refs></ce:para><ce:para>Acetaminophen has mild to moderate analgesic properties as well as antipyretic activity. Acetaminophen has been used for a wide variety of indications, including fever and pain associated with many different conditions.<ce:cross-ref refid="bib45"><ce:sup>45</ce:sup></ce:cross-ref> Contributing to acetaminophen&apos;s widespread use is its easy tolerability. Unlike NSAIDs, acetaminophen does not affect platelet function or uric acid levels, nor is it associated with significant gastrointestinal toxicity.<ce:cross-ref refid="bib45"><ce:sup>45</ce:sup></ce:cross-ref> Acetaminophen is felt to be safe in patients with peptic ulcer disease and aspirin hypersensitivity, but is not a reasonable alternative to NSAIDs in patients with inflammatory conditions such as rheumatoid arthritis.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref> Side effects that have been reported, albeit infrequently, include rash, hypersensitivity reactions, blood dyscrasias, and renal toxicity.<ce:cross-ref refid="bib45"><ce:sup>45</ce:sup></ce:cross-ref></ce:para><ce:para>The most serious adverse event that may occur with acetaminophen is the risk for hepatotoxicity that occurs with overdose. The maximum adult dose of acetaminophen is 4000 mg per day and for those with chronic alcohol use, 2000 mg daily (<ce:cross-ref refid="tbl5">Table 5</ce:cross-ref><ce:float-anchor refid="tbl5"/>).<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref> Because of the vast number of preparations that contain acetaminophen, including prescription and OTC, accidental overdose can occur due to consumption of multiple products (ie, prescription analgesic agents and OTC cough and cold preparations). Whether accidental or intentional, acetaminophen overdose is a medical emergency.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref> Overdose can occur with single doses of 10 to 15 g, and doses of 20 to 25 g can be lethal.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref> Acetaminophen toxicity is divided into 4 stages. The first stage can occur within several hours of acute ingestion, is typically associated with nausea, vomiting, and stomach pain, and may resolve within 24 hours.<ce:cross-refs refid="bib14 bib45"><ce:sup>14,45</ce:sup></ce:cross-refs> The second stage can start approximately 12 to 36 hours after acute ingestion, and is significant for right upper quadrant pain and elevated liver enzymes.<ce:cross-ref refid="bib45"><ce:sup>45</ce:sup></ce:cross-ref> Stage 3 occurs 72 to 96 hours after ingestion of toxic doses, and hepatomegaly, jaundice, and coagulopathy may be present.<ce:cross-refs refid="bib14 bib45"><ce:sup>14,45</ce:sup></ce:cross-refs> Liver enzyme levels peak during this time period and renal failure can be present. The onset of encephalopathy or worsening coagulopathy after this time period indicates a poor prognosis.<ce:cross-ref refid="bib14"><ce:sup>14</ce:sup></ce:cross-ref> Stage 4 is the recovery period for those who make it past stage 3.<ce:cross-ref refid="bib45"><ce:sup>45</ce:sup></ce:cross-ref> Acetaminophen overdose is best managed when early diagnosis and treatment can occur. It has been estimated that about 10% of those who do not receive proper treatment will develop severe hepatic impairment, and 10% to 20% of those may eventually die from liver failure.<ce:cross-refs refid="bib14 bib45"><ce:sup>14,45</ce:sup></ce:cross-refs></ce:para><ce:para>Several studies have evaluated acetaminophen and compared it with an NSAID for treating pain. A study by Dalton and Schweinle<ce:cross-ref refid="bib46"><ce:sup>46</ce:sup></ce:cross-ref> compared acetaminophen extended-release to ibuprofen in 260 patients who presented with grade I or II lateral ankle sprains. At the end of the study, acetaminophen was found to be not inferior to ibuprofen; 78% to 80% of patients had resumed normal activities, and mean time to resumption was approximately 4 days in both groups.<ce:cross-ref refid="bib46"><ce:sup>46</ce:sup></ce:cross-ref> A study by Woo and colleagues<ce:cross-ref refid="bib47"><ce:sup>47</ce:sup></ce:cross-ref> recruited 300 patients who presented to an emergency room with an isolated painful limb injury. Patients were randomized to a 3-day course of acetaminophen, indomethacin, diclofenac, or acetaminophen and diclofenac. Pain reduction was seen in all treatment arms, with score reductions not found to be clinically or statistically significant among the 4 groups over the course of the 3 days.<ce:cross-ref refid="bib47"><ce:sup>47</ce:sup></ce:cross-ref> The combination therapy group had the greatest reduction in pain scores at each time point but also produced more side effects, including abdominal pain.<ce:cross-ref refid="bib47"><ce:sup>47</ce:sup></ce:cross-ref> Although the literature is not as extensive as for NSAIDs regarding the use of acetaminophen for treating musculoskeletal injuries, there is evidence to support its use.</ce:para></ce:section></ce:section><ce:section id="sec8"><ce:section-title>Topical nonprescription analgesics</ce:section-title><ce:para>Nonprescription, or OTC, analgesic agents and external counterirritants are widely used in the United States, with more than $2 billion spent on them each year.<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref> Due to their easy access without a prescription, OTC topical analgesics are often first used in treating acute injuries before scheduling a visit to the physician. Topical analgesics can have one of several different properties; those with counterirritant effects are indicated for the acute treatment of minor aches and pains. Counterirritants exert their effect by producing a less intense pain than the pain the individual is experiencing.<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref> The perception of another sensation distracts the person from the original pain produced by the injury. Counterirritants can fall into 1 of 4 categories based on their mechanism: (1) act as rubefacients, (2) production of a cooling sensation, (3) producing vasodilation, and (4) causing irritation without rubefaction.<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref> A classification of topical analgesics with counterirritant properties is outlined in <ce:cross-ref refid="tbl6">Table 6</ce:cross-ref><ce:float-anchor refid="tbl6"/>. The FDA has approved these agents for use in treating minor aches and pain for both adults and children 2 years or older.<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref> Counterirritants from different categories are often combined in various preparations to enhance the efficacy of the product.</ce:para><ce:section id="sec8.1"><ce:section-title>Methyl Salicylate</ce:section-title><ce:para>Methyl salicylate is a commonly used rubefacient that is available naturally in wintergreen oil, or it can be produced by esterification of salicylic acid with methyl alcohol.<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref> Methyl salicylate is thought to exert its effect by producing a local vasodilation, and the counterirritant effect results from the local increase in skin temperature.<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref> Most of the effects of methyl salicylate are locally mediated; however, systemic absorption can increase with the use of multiple applications, and use with local application of heat and occlusive dressings.<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref> The most common adverse effects are skin irritation and rash, but more severe skin reactions along with systemic toxicity can occur.<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref> The use of heating pads should be avoided while using topical methyl salicylate because tissue and muscle necrosis along with interstitial nephritis have been reported when topical methyl salicylate and menthol were used.<ce:cross-ref refid="bib49"><ce:sup>49</ce:sup></ce:cross-ref> Methyl salicylate should be avoided in children and in individuals with aspirin sensitivity and asthma, due to the risk for systemic absorption.<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref> Drug interactions with warfarin have been reported with typical and high-dose topical methyl salicylate, resulting in an elevation of the prothrombin time/international normalized ratio.<ce:cross-refs refid="bib50 bib51"><ce:sup>50,51</ce:sup></ce:cross-refs></ce:para></ce:section><ce:section id="sec8.2"><ce:section-title>Camphor</ce:section-title><ce:para>Most camphor is synthetically produced and exerts a counterirritant effect via a cooling sensation. Camphor stimulates skin nerve endings producing mild pain, which allows for a masking of the deeper-seated pain.<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref> The major toxicity associated with camphor is tonic-clonic seizures. The risk for toxicity correlates with the amount and extent of the camphor ingested.<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref> In addition to seizures, high doses have also been associated with nausea, vomiting, dizziness, delirium, coma, and death.<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref> Concentrations of camphor oil at 20% and as little as 5 mL can be lethal when ingested by children.<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref> As a result, in 1982 the FDA ruled that camphorated oil products could no longer be produced and products containing camphor must have concentrations less than 11% to be considered safe for nonprescription use.<ce:cross-ref refid="bib52"><ce:sup>52</ce:sup></ce:cross-ref> Unfortunately, pediatric cases of toxicity from acute ingestions have continued to be reported with OTC preparations containing camphor.<ce:cross-refs refid="bib48 bib52 bib53"><ce:sup>48,52,53</ce:sup></ce:cross-refs></ce:para></ce:section><ce:section id="sec8.3"><ce:section-title>Menthol</ce:section-title><ce:para>Menthol, prepared synthetically or derived from peppermint oil, is another counterirritant when used at concentrations greater than 1.25%.<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref> Menthol exerts its cooling effect by activating the transient receptor potential, TRPM8, in sensory neurons.<ce:cross-ref refid="bib54"><ce:sup>54</ce:sup></ce:cross-ref> Menthol has also been associated with an increase in local blood flow at the application site, resulting in a warm sensation.<ce:cross-ref refid="bib54"><ce:sup>54</ce:sup></ce:cross-ref> Menthol has been associated with a low incidence of hypersensitivity reactions including itching, erythema, and skin lesions, and postmarketing data indicate minimal toxicity.<ce:cross-ref refid="bib54"><ce:sup>54</ce:sup></ce:cross-ref></ce:para></ce:section><ce:section id="sec8.4"><ce:section-title>Capsaicin</ce:section-title><ce:para>Capsaicin, which is derived from hot chili peppers, produces an analgesic effect due to its direct irritant properties. Topical application of capsaicin produces a warm sensation locally due to activation of the TRP vanilloid (TRPV1); this effect decreases with repeated administration due to tachyphylaxis.<ce:cross-refs refid="bib55 bib56"><ce:sup>55,56</ce:sup></ce:cross-refs> Capsaicin depletes substance P (neurotransmitter for pain communication) from unmyelinated type C sensory neurons, which can produce an initial burning or itching sensation.<ce:cross-ref refid="bib57"><ce:sup>57</ce:sup></ce:cross-ref> Blockade of further synthesis of substance P with repeated application leads to persistent desensitization.<ce:cross-ref refid="bib57"><ce:sup>57</ce:sup></ce:cross-ref> The burning sensation diminishes with repeated use, but can lead to an increase in nonadherence and discontinuation of its use. Topical capsaicin has been recommended for use in osteoarthritis, and pain relief is usually seen within several weeks. Capsaicin is applied routinely 3 to 4 times daily to sustain its effect. Gloves should be used to minimize contact with mucous membranes.<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref> As with other topical analgesics, capsaicin should not be applied to open wounds and should be discontinued if skin breakdown occurs.<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref> Capsaicin has not been studied in acute sports-related injuries, and given that its analgesic effects may not be seen for several weeks, may make it less ideal for treatment.</ce:para></ce:section><ce:section id="sec8.5"><ce:section-title>Others</ce:section-title><ce:para>Other counterirritants not widely used include turpentine oil, histamine dihydrochloride, and ammonia water.<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref> The efficacy of these agents is difficult to evaluate, because they are often used in combination with other counterirritant agents. Little data exist to support the use of eucalyptus oil and trolamine salicylate; however, trolamine salicylate continues to be available in a variety of topical analgesics. Trolamine salicylate is not a counterirritant and has been shown to be systemically absorbed.<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref> In general, for trolamine salicylate 10% to 15%, is applied to the skin 3 to 4 times daily.<ce:cross-ref refid="bib48"><ce:sup>48</ce:sup></ce:cross-ref> Contraindications, precautions, and drug interactions are similar to those of salicylates. Trolamine may be beneficial for those who are unable to tolerate other counterirritants or find them unacceptable.</ce:para><ce:para>Counterirritants are available in a wide variety of single and combination products as nonprescription analgesic agents (<ce:cross-ref refid="tbl7">Table 7</ce:cross-ref><ce:float-anchor refid="tbl7"/>). Counterirritants are indicated for the treatment of mild aches and pains related to acute injury, and provide a useful option for self-treatment. General guidelines for use of topical counterirritant agents are outlined in <ce:cross-ref refid="tbox1">Box 1</ce:cross-ref><ce:float-anchor refid="tbox1"/>.</ce:para></ce:section></ce:section><ce:section id="sec9"><ce:section-title>Use and abuse of analgesics</ce:section-title><ce:para>OTC medications are widely available and used in the United States. It is not uncommon for individuals to self treat for a wide variety of ailments, including acute musculoskeletal injuries. It has been estimated that 30% of adults have used one or more OTC medications within the past 2 days.<ce:cross-ref refid="bib59"><ce:sup>59</ce:sup></ce:cross-ref> Children and adolescents are also consumers of OTC medications for cough and cold, headache, fever, menstrual, and joint and muscle pain. Chambers and colleagues,<ce:cross-ref refid="bib59"><ce:sup>59</ce:sup></ce:cross-ref> administered a questionnaire to 651 junior high school students in Nova Scotia to evaluate the use of OTC medications, indications, and self-administration. Of those who used an OTC medication, 88% reported using it for muscle, joint, and back pain; acetaminophen was the most common medication used for each type of pain assessed.<ce:cross-ref refid="bib59"><ce:sup>59</ce:sup></ce:cross-ref> Self-administration was common, with 58% to 76% reporting taking medication within the past 3 months without consulting any knowledgeable professional.<ce:cross-ref refid="bib59"><ce:sup>59</ce:sup></ce:cross-ref></ce:para><ce:para>With increasing self-administration and easily accessibility, factors that influence consumption of OTC medications have been evaluated. Van den Bulck and colleagues<ce:cross-ref refid="bib60"><ce:sup>60</ce:sup></ce:cross-ref> evaluated the association between watching television and analgesic use in 2545 Belgian students (aged 13&ndash;16 years). Using a questionnaire, the investigators found that the use of analgesics differed among school years and between gender. A significant correlation was found between regular OTC analgesic use (at least monthly) and viewing of television (odds ratio [OR] 1.16, 95% CI: 1.08&ndash;1.24).<ce:cross-ref refid="bib60"><ce:sup>60</ce:sup></ce:cross-ref> Playing video games and Internet use was not significantly associated with analgesic use. The authors note that this study did not evaluate the extent to which adolescents were exposed to advertisements during television viewing.<ce:cross-ref refid="bib60"><ce:sup>60</ce:sup></ce:cross-ref></ce:para><ce:para>Self-administration of medications by children and adolescents can be influenced by multiple factors and is potentially dangerous. Huott and Storrow<ce:cross-ref refid="bib61"><ce:sup>61</ce:sup></ce:cross-ref> surveyed 203 adolescents aged 13 to 18 years who presented to an emergency room or acute care clinic. The adolescents completed a 1-page survey assessing their knowledge of OTC medication toxicity. An informal survey of the investigators&apos; colleagues and standard texts served as the reference point regarding medication toxicity.<ce:cross-ref refid="bib61"><ce:sup>61</ce:sup></ce:cross-ref> Survey results of the adolescents indicated that 63% considered aspirin, 57% acetaminophen, 24% iron, 22% camphor, and 17% to 21% methyl salicylate to be nonlethal, which was contradictory to the faculty&apos;s viewpoint.<ce:cross-ref refid="bib61"><ce:sup>61</ce:sup></ce:cross-ref> The results of this study emphasize that education regarding the toxicity of OTC medications needs further emphasis.</ce:para><ce:para>While analgesic use is common among adolescents in general, the pattern of their use among student athletes in particular has not been clearly elucidated. Many student athletes experience muscle aches and pains as well as sports-related injuries, and may self-medicate with OTC analgesic agents including NSAIDs. Evidence indicates that many adolescents are unaware of the potential toxicity or risk for side effects associated with nonprescription analgesic medications. Warner and colleagues<ce:cross-ref refid="bib62"><ce:sup>62</ce:sup></ce:cross-ref> distributed a self-administered questionnaire to 604 high school football athletes to compare users with nonusers of NSAIDs and discern differences in attitudes regarding daily use of NSAIDs. The study found that 75% had used NSAIDs in the past 3 months.<ce:cross-ref refid="bib62"><ce:sup>62</ce:sup></ce:cross-ref> Of this cohort, 15% considered themselves daily users of NSAIDs.<ce:cross-ref refid="bib62"><ce:sup>62</ce:sup></ce:cross-ref> After controlling for confounding variables, those who perceived that NSAIDs enhanced performance (adjusted odds ratio [AOR] 2.4; 95% CI 1.4&ndash;4.1), those who used prophylactic NSAIDs (AOR 2.5; 95% CI 1.5&ndash;4.3), and those who self-administered NSAIDs (AOR 2.2; 95% CI 1.01&ndash;4.9), were more likely to take NSAIDs on a daily basis.<ce:cross-ref refid="bib62"><ce:sup>62</ce:sup></ce:cross-ref></ce:para><ce:para>Often in athletes, student as well as elite, studies focus on medications of abuse rather than common prescription and nonprescription medications. Alaranta and colleagues<ce:cross-ref refid="bib63"><ce:sup>63</ce:sup></ce:cross-ref> used a questionnaire to determine the frequency of prescribed medications in a group of elite athletes. In 2002, 446 athletes, supported by the National Olympic Committee, completed the survey and were matched to 1503 controls obtained from a population-based study done by the National Public Health Institute.<ce:cross-ref refid="bib63"><ce:sup>63</ce:sup></ce:cross-ref> Among athletes, within the previous 7 days 34.5% were using a prescription medication compared with approximately 25% of the controls.<ce:cross-ref refid="bib63"><ce:sup>63</ce:sup></ce:cross-ref> NSAIDs were among the most frequently prescribed medications (8.1%) in athletes, with an AOR of 3.63 (95% CI: 2.25&ndash;5.84) for use within the past 7 days.<ce:cross-ref refid="bib63"><ce:sup>63</ce:sup></ce:cross-ref> Adverse events were reported in 20% of NSAID users.<ce:cross-ref refid="bib63"><ce:sup>63</ce:sup></ce:cross-ref></ce:para></ce:section><ce:section id="sec10"><ce:section-title>Summary</ce:section-title><ce:para>The idea of &ldquo;no pain, no gain&rdquo; is a common misperception that should be dispelled. Muscle soreness can be expected with strenuous activity or due to an unaccustomed activity, but significant pain is the body&apos;s response that rest should occur to allow for healing.<ce:cross-ref refid="bib6"><ce:sup>6</ce:sup></ce:cross-ref> Too often, athletes do not take the time off from training or competition to allow for adequate healing.<ce:cross-ref refid="bib64"><ce:sup>64</ce:sup></ce:cross-ref> By using analgesics, in particular NSAIDs, pain may subside but further damage can result from continued exercise. Also, NSAIDs, via their inhibition of prostaglandins, may impede the healing process and muscle regeneration after an acute injury. While these agents are relatively safe they are not without side effects, and caution is warranted. There is only limited evidence (albeit it conflicting) in DOMS that NSAIDs can provide a benefit as prophylactic therapy.</ce:para><ce:para>Overall, analgesic agents, including NSAIDs, acetaminophen, and topical OTC agents, can effectively relieve pain associated with acute or chronic musculoskeletal injury. Data regarding the ability of NSAIDs to improve muscle recovery and allow a quicker return to activity remain controversial. This area of focus has not been adequately studied with acetaminophen and topical OTC analgesics. When considering an analgesic for alleviating pain, the lowest dose for the shortest time interval should be used. Risk for side effects should be considered and compared with the benefits of the medication. Long-term use for symptoms of sport-related injuries should be avoided, especially with NSAIDs, due to their side effect profile and concern for their impeding the healing process. Data do not adequately support the use of prophylactic NSAIDs prior to sporting events, and should be avoided.</ce:para></ce:section></ce:sections><ce:acknowledgment><ce:section-title>Acknowledgments</ce:section-title><ce:para>The authors thank Kim Douglas and Amy Esman, Kalamazoo Center for Medical Studies, for assistance in the preparation of this article.</ce:para></ce:acknowledgment></body><tail><ce:bibliography><ce:section-title>References</ce:section-title><ce:bibliography-sec><ce:bib-reference id="bib1"><ce:label>1</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Almekinders</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Anti-inflammatory treatment of muscular injuries in sport, an update of recent studies</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Sports Med</sb:maintitle></sb:title><sb:volume-nr>28</sb:volume-nr></sb:series><sb:issue-nr>6</sb:issue-nr><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>383</sb:first-page><sb:last-page>388</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib2"><ce:label>2</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>W.E.</ce:given-name><ce:surname>Garrett</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Muscle strain injuries: clinical and basic aspects</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Med Sci Sports Exerc</sb:maintitle></sb:title><sb:volume-nr>22</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>436</sb:first-page><sb:last-page>443</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib3"><ce:label>3</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Mehallo</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Drezner</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Bytomski</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Practical management: nonsteroidal anti-inflammatory drug (NSAID) use in athletic injuries</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin J Sport Med</sb:maintitle></sb:title><sb:volume-nr>16</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>170</sb:first-page><sb:last-page>174</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib4"><ce:label>4</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Micheli</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Common painful sports injuries: assessment and treatment</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin J Pain</sb:maintitle></sb:title><sb:volume-nr>5</sb:volume-nr></sb:series><sb:issue-nr>Suppl 2</sb:issue-nr><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>S51</sb:first-page><sb:last-page>S60</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib5"><ce:label>5</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Howatson</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>van Someren</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The prevention and treatment of exercise-induced muscle damage</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Sports Med</sb:maintitle></sb:title><sb:volume-nr>38</sb:volume-nr></sb:series><sb:issue-nr>6</sb:issue-nr><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>483</sb:first-page><sb:last-page>503</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib6"><ce:label>6</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Smith</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Collina</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Pain medications in the locker room: to dispense or not</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Curr Sports Med Rep</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>367</sb:first-page><sb:last-page>370</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib7"><ce:label>7</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>L.C.</ce:given-name><ce:surname>Almekinders</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Gilbert</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Healing of experimental muscle strains and the effects of non-steroidal anti-inflammatory medication</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am J Sports Med</sb:maintitle></sb:title><sb:volume-nr>14</sb:volume-nr></sb:series><sb:date>1986</sb:date></sb:issue><sb:pages><sb:first-page>303</sb:first-page><sb:last-page>308</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib8"><ce:label>8</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>J.J.</ce:given-name><ce:surname>Crisco</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Jokl</ce:surname></sb:author><sb:author><ce:given-name>G.T.</ce:given-name><ce:surname>Heinen</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>A muscle contusion injury model: biomechanics, physiology and histology</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am J Sports Med</sb:maintitle></sb:title><sb:volume-nr>22</sb:volume-nr></sb:series><sb:date>1994</sb:date></sb:issue><sb:pages><sb:first-page>702</sb:first-page><sb:last-page>710</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib9"><ce:label>9</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>J.G.</ce:given-name><ce:surname>Tidball</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Inflammatory cell response to acute muscle injury</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Med Sci Sports Exerc</sb:maintitle></sb:title><sb:volume-nr>27</sb:volume-nr></sb:series><sb:date>1995</sb:date></sb:issue><sb:pages><sb:first-page>1022</sb:first-page><sb:last-page>1032</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib10"><ce:label>10</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Kuipers</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Exercise-induced muscle damage</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Int J Sports Med</sb:maintitle></sb:title><sb:volume-nr>15</sb:volume-nr></sb:series><sb:date>1994</sb:date></sb:issue><sb:pages><sb:first-page>132</sb:first-page><sb:last-page>135</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib11"><ce:label>11</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>T.A.</ce:given-name><ce:surname>Jarvinen</ce:surname></sb:author><sb:author><ce:given-name>T.L.</ce:given-name><ce:surname>Jarvinen</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Kaariainen</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Muscle injuries biology and treatment</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am J Sports Med</sb:maintitle></sb:title><sb:volume-nr>33</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>745</sb:first-page><sb:last-page>764</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib12"><ce:label>12</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Maroon</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Bost</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Borden</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Natural anti-inflammatory agents for pain relief in athletes</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurosurg Focus</sb:maintitle></sb:title><sb:volume-nr>21</sb:volume-nr></sb:series><sb:issue-nr>4</sb:issue-nr><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>E11</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib13"><ce:label>13</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Herndon</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Hutchinson</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Berdine</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Management of chronic nonmalignant pain with nonsteroidal anti-inflammatory drugs</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Pharmacotherapy</sb:maintitle></sb:title><sb:volume-nr>28</sb:volume-nr></sb:series><sb:issue-nr>6</sb:issue-nr><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>788</sb:first-page><sb:last-page>805</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib14"><ce:label>14</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Burke</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Smyth</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>FitzGerald</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Analgesic-antipyretic and antiinflammatory agents; pharmacotherapy of gout</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:editors><sb:editor><ce:given-name>L.</ce:given-name><ce:surname>Brunton</ce:surname></sb:editor><sb:editor><ce:given-name>J.</ce:given-name><ce:surname>Lazo</ce:surname></sb:editor><sb:editor><ce:given-name>K.</ce:given-name><ce:surname>Parker</ce:surname></sb:editor></sb:editors><sb:title><sb:maintitle>Goodman and Gilman&apos;s, the pharmacological basis of therapeutics</sb:maintitle></sb:title><sb:edition>11th edition</sb:edition><sb:date>2006</sb:date><sb:publisher><sb:name>McGraw-Hill</sb:name><sb:location>New York</sb:location></sb:publisher></sb:edited-book><sb:pages><sb:first-page>671</sb:first-page><sb:last-page>715</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib15"><ce:label>15</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Vane</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Botting</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Mechanism of action of nonsteroidal anti-inflammatory drugs</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am J Med</sb:maintitle></sb:title><sb:volume-nr>104</sb:volume-nr></sb:series><sb:issue-nr>3A</sb:issue-nr><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>2S</sb:first-page><sb:last-page>8S</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib16"><ce:label>16</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Furst Daniel</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Ulrich Robert</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Varkey-Altamirano</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics, drugs used in gout</sb:maintitle></sb:title></sb:contribution><sb:comment>In: Bertram GK, Susan BM, Anthony JT, editors. Basic &amp; clinical pharmacology. 11th edition. Chapter 36. Available at:</sb:comment><sb:host><sb:e-host><ce:inter-ref xlink:href="http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aID=4519955">http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aID&equals;4519955</ce:inter-ref></sb:e-host></sb:host><sb:comment>Accessed February 5, 2010</sb:comment></sb:reference></ce:bib-reference><ce:bib-reference id="bib17"><ce:label>17</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Smyth Emer</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>FitzGerald Garret</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The eicosanoids: prostaglandins, thromboxanes, leukotrienes, related compounds</sb:maintitle></sb:title></sb:contribution><sb:comment>In: Bertram GK, Susan BM, Anthony JT, editors. Basic &amp; clinical pharmacology. 11th edition. Chapter 18. Available at:</sb:comment><sb:host><sb:e-host><ce:inter-ref xlink:href="http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aID=4518588">http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aID&equals;4518588</ce:inter-ref></sb:e-host></sb:host><sb:comment>Accessed February 5, 2010</sb:comment></sb:reference></ce:bib-reference><ce:bib-reference id="bib18"><ce:label>18</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Vane</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Botting</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The mechanism of action of aspirin</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Thromb Res</sb:maintitle></sb:title><sb:volume-nr>110</sb:volume-nr></sb:series><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>255</sb:first-page><sb:last-page>258</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib19"><ce:label>19</ce:label><ce:other-ref><ce:textref>Lexi-Comp, Inc (Lexi-Drugs<ce:sup>&reg;</ce:sup>). Lexi-Comp. Accessed December 21, 2009.</ce:textref></ce:other-ref></ce:bib-reference><ce:bib-reference id="bib20"><ce:label>20</ce:label><sb:reference><sb:contribution><sb:title><sb:maintitle>Natural medicines comprehensive database [database on the Internet]</sb:maintitle></sb:title></sb:contribution><sb:comment>Stockton (CA): Therapeutic Research Faculty; c1995&ndash;2009. Antiplatelet; [about 14 pages]. Available at:</sb:comment><sb:host><sb:e-host><ce:inter-ref xlink:href="http://www.naturaldatabase.com/(S(wqklte55rbhkbvzskfpaim45))/nd/Search.aspx?cs=MHSLA%7ECP&amp;s=ND&amp;pt=9&amp;Product=antiplatelet">http://www.naturaldatabase.com/(S(wqklte55rbhkbvzskfpaim45))/nd/Search.aspx?cs&equals;MHSLA%7ECP&amp;s&equals;ND&amp;pt&equals;9&amp;Product&equals;antiplatelet</ce:inter-ref></sb:e-host></sb:host><sb:comment>Accessed December 21, 2009</sb:comment></sb:reference></ce:bib-reference><ce:bib-reference id="bib21"><ce:label>21</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Kirchain</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Allen</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Drug-induced liver disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:editors><sb:editor><ce:given-name>J.</ce:given-name><ce:surname>DiPiro</ce:surname></sb:editor><sb:editor><ce:given-name>R.</ce:given-name><ce:surname>Talbert</ce:surname></sb:editor><sb:editor><ce:given-name>G.</ce:given-name><ce:surname>Yee</ce:surname></sb:editor><sb:et-al/></sb:editors><sb:title><sb:maintitle>Pharmacotherapy a pathophysiologic approach</sb:maintitle></sb:title><sb:edition>7th edition</sb:edition><sb:date>2008</sb:date><sb:publisher><sb:name>McGraw-Hill</sb:name><sb:location>New York</sb:location></sb:publisher></sb:edited-book><sb:pages><sb:first-page>652</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib22"><ce:label>22</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>J.M.</ce:given-name><ce:surname>Scheiman</ce:surname></sb:author><sb:author><ce:given-name>A.M.</ce:given-name><ce:surname>Fendrick</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Arthritis Res Ther</sb:maintitle></sb:title><sb:volume-nr>7</sb:volume-nr></sb:series><sb:issue-nr>Suppl 4</sb:issue-nr><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>S23</sb:first-page><sb:last-page>S29</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib23"><ce:label>23</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>J.L.</ce:given-name><ce:surname>Golstein</ce:surname></sb:author><sb:author><ce:given-name>G.M.</ce:given-name><ce:surname>Eisen</ce:surname></sb:author><sb:author><ce:given-name>T.A.</ce:given-name><ce:surname>Burke</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Dyspepsia tolerability from the patients&apos; perspective: a comparison of celecoxib with diclofenac</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Aliment Pharmacol Ther</sb:maintitle></sb:title><sb:volume-nr>16</sb:volume-nr></sb:series><sb:date>2002</sb:date></sb:issue><sb:pages><sb:first-page>819</sb:first-page><sb:last-page>827</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib24"><ce:label>24</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Bombardier</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Laine</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Reicin</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>N Engl J Med</sb:maintitle></sb:title><sb:volume-nr>343</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>1520</sb:first-page><sb:last-page>1528</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib25"><ce:label>25</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Laine</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Nonsteroidal anti-inflammatory drug gastropathy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Gastrointest Endosc Clin N Am</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>489</sb:first-page><sb:last-page>504</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib26"><ce:label>26</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>S.E.</ce:given-name><ce:surname>Gabriel</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Jaakkimainen</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Bombardier</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann Intern Med</sb:maintitle></sb:title><sb:volume-nr>115</sb:volume-nr></sb:series><sb:date>1991</sb:date></sb:issue><sb:pages><sb:first-page>787</sb:first-page><sb:last-page>796</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib27"><ce:label>27</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Ekstrom</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Carling</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Wetterhuis</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous nonsteroidal anti-inflammatory drug therapy: a Nordic multicentre study</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Scand J Gastroenterol</sb:maintitle></sb:title><sb:volume-nr>31</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>753</sb:first-page><sb:last-page>758</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib28"><ce:label>28</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Hippisley-Cox</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Coupland</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Logan</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>BMJ</sb:maintitle></sb:title><sb:volume-nr>331</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>1310</sb:first-page><sb:last-page>1316</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib29"><ce:label>29</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Bennett</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Turmelle</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Shepherd</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Ibuprofen-induced liver injury in an adolescent athlete</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin Pediatr</sb:maintitle></sb:title><sb:volume-nr>48</sb:volume-nr></sb:series><sb:issue-nr>1</sb:issue-nr><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>84</sb:first-page><sb:last-page>86</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib30"><ce:label>30</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>J.H.</ce:given-name><ce:surname>Rubenstein</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Laine</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Aliment Pharmacol Ther</sb:maintitle></sb:title><sb:volume-nr>20</sb:volume-nr></sb:series><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>373</sb:first-page><sb:last-page>380</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib31"><ce:label>31</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Rostom</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Goldkind</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Laine</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin Gastroenterol Hepatol</sb:maintitle></sb:title><sb:volume-nr>3</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>489</sb:first-page><sb:last-page>498</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib32"><ce:label>32</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Whelton</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am J Med</sb:maintitle></sb:title><sb:volume-nr>106</sb:volume-nr></sb:series><sb:issue-nr>Suppl 5B</sb:issue-nr><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>S13</sb:first-page><sb:last-page>S24</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib33"><ce:label>33</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>D.M.</ce:given-name><ce:surname>Clive</ce:surname></sb:author><sb:author><ce:given-name>J.S.</ce:given-name><ce:surname>Stoff</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Renal syndromes associated with nonsteroidal anti-inflammatory drugs</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>N Engl J Med</sb:maintitle></sb:title><sb:volume-nr>310</sb:volume-nr></sb:series><sb:date>1984</sb:date></sb:issue><sb:pages><sb:first-page>563</sb:first-page><sb:last-page>572</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib34"><ce:label>34</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>W.L.</ce:given-name><ce:surname>Henrich</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Nephrotoxicity of nonsteroidal anti-inflammatory agents</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am J Kidney Dis</sb:maintitle></sb:title><sb:volume-nr>2</sb:volume-nr></sb:series><sb:date>1983</sb:date></sb:issue><sb:pages><sb:first-page>478</sb:first-page><sb:last-page>484</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib35"><ce:label>35</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Nakahura</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Griswold</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Lemire</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Nonsteroidal anti-inflammatory drug use in adolescents</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Adolesc Health</sb:maintitle></sb:title><sb:volume-nr>23</sb:volume-nr></sb:series><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>307</sb:first-page><sb:last-page>310</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib36"><ce:label>36</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Solomon</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>McMurray</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Pfeffer</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>N Engl J Med</sb:maintitle></sb:title><sb:volume-nr>352</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>1071</sb:first-page><sb:last-page>1080</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib37"><ce:label>37</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>R.S.</ce:given-name><ce:surname>Bresalier</ce:surname></sb:author><sb:author><ce:given-name>R.S.</ce:given-name><ce:surname>Sandler</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Quan</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>N Engl J Med</sb:maintitle></sb:title><sb:volume-nr>352</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>1092</sb:first-page><sb:last-page>1102</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib38"><ce:label>38</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>P.</ce:given-name><ce:surname>McGettigan</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Henry</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Cardiovascular risk and inhibition of cyclooxygenase, a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>JAMA</sb:maintitle></sb:title><sb:volume-nr>296</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>1633</sb:first-page><sb:last-page>1644</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib39"><ce:label>39</ce:label><sb:reference><sb:contribution><sb:title><sb:maintitle>COX-2 selective (includes Bextra, Celebrex, and Vioxx) and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). U.S. Food and Drug Administration, Drug Safety and Availability</sb:maintitle></sb:title></sb:contribution><sb:comment>Available at:</sb:comment><sb:host><sb:e-host><ce:inter-ref xlink:href="http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103420.htm">http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103420.htm</ce:inter-ref></sb:e-host></sb:host><sb:comment>Updated September 24, 2009. Accessed December 28, 2009</sb:comment></sb:reference></ce:bib-reference><ce:bib-reference id="bib40"><ce:label>40</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:surname>Drug Facts &amp; Comparisons [database on the Internet]</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Facts &amp; comparisons</sb:maintitle></sb:title></sb:contribution><sb:comment>Indianapolis (IN). 4.0; 2009. Nonsteroidal anti-inflammatory agents; [about 21 pages]. Available at:</sb:comment><sb:host><sb:e-host><ce:inter-ref xlink:href="http://0-online.factsandcomparisons.com.libcat.ferris.edu/MonoDispaspx?id=570727&amp;book=DFC">http://0-online.factsandcomparisons.com.libcat.ferris.edu/MonoDispaspx?id&equals;570727&amp;book&equals;DFC</ce:inter-ref></sb:e-host></sb:host><sb:comment>Accessed December 28, 2009</sb:comment></sb:reference></ce:bib-reference><ce:bib-reference id="bib41"><ce:label>41</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Lanier</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Use of nonsteroidal anti-inflammatory drugs following exercise-induced muscle injury</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Sports Med</sb:maintitle></sb:title><sb:volume-nr>3</sb:volume-nr></sb:series><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>177</sb:first-page><sb:last-page>186</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib42"><ce:label>42</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Moore</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Tramer</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Carroll</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>BMJ</sb:maintitle></sb:title><sb:volume-nr>316</sb:volume-nr></sb:series><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>333</sb:first-page><sb:last-page>338</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib43"><ce:label>43</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Peterson</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Rovati</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Diclofenac epolamine (Flector<ce:sup>&reg;</ce:sup>) patch, evidence for topical activity</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin Drug Investig</sb:maintitle></sb:title><sb:volume-nr>29</sb:volume-nr></sb:series><sb:issue-nr>1</sb:issue-nr><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>1</sb:first-page><sb:last-page>9</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib44"><ce:label>44</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Zacher</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Altman</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Bellamy</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Topical diclofenac and its role in pain and&nbsp;inflammation: an evidence-based review</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Curr Med Res Opin</sb:maintitle></sb:title><sb:volume-nr>24</sb:volume-nr></sb:series><sb:issue-nr>4</sb:issue-nr><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>925</sb:first-page><sb:last-page>950</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib45"><ce:label>45</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:surname>Drug Facts &amp; Comparisons [database on the Internet]</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Facts &amp; comparisons</sb:maintitle></sb:title></sb:contribution><sb:comment>Indianapolis (IN). 4.0; 2009. Acetaminophen; [about 5 pages]. Available at:</sb:comment><sb:host><sb:e-host><ce:inter-ref xlink:href="http://0-online.factsandcomparisons.com.libcat.ferris.edu/MonoDisp.aspx?monoID=fandc-hcp10022&amp;quick=acetaminophen&amp;search=acetaminophen&amp;disease=">http://0-online.factsandcomparisons.com.libcat.ferris.edu/MonoDisp.aspx?monoID&equals;fandc-hcp10022&amp;quick&equals;acetaminophen&amp;search&equals;acetaminophen&amp;disease&equals;</ce:inter-ref></sb:e-host></sb:host><sb:comment>Accessed December 31, 2009</sb:comment></sb:reference></ce:bib-reference><ce:bib-reference id="bib46"><ce:label>46</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Dalton</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Schweinle</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Randomized controlled noninferiority trial to compare extended release acetaminophen and ibuprofen for the treatment of ankle sprains</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann Emerg Med</sb:maintitle></sb:title><sb:volume-nr>48</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>615</sb:first-page><sb:last-page>623</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib47"><ce:label>47</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Woo</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Man</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Lam</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Randomized double-blind trial comparing oral paracetamol and oral nonsteroidal anti-inflammatory drugs for treating pain after musculoskeletal injury</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann Emerg Med</sb:maintitle></sb:title><sb:volume-nr>46</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>352</sb:first-page><sb:last-page>361</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib48"><ce:label>48</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Wright</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Musculoskeletal injuries and disorders</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:editors><sb:editor><ce:given-name>R.</ce:given-name><ce:surname>Berardi</ce:surname></sb:editor><sb:editor><ce:given-name>S.</ce:given-name><ce:surname>Ferreri</ce:surname></sb:editor><sb:editor><ce:given-name>A.</ce:given-name><ce:surname>Hume</ce:surname></sb:editor><sb:et-al/></sb:editors><sb:title><sb:maintitle>Handbook of nonprescription drugs, an interactive approach to self-care</sb:maintitle></sb:title><sb:edition>16th edition</sb:edition><sb:date>2009</sb:date><sb:publisher><sb:name>American Pharmacists Association</sb:name><sb:location>Washington, DC</sb:location></sb:publisher></sb:edited-book><sb:pages><sb:first-page>95</sb:first-page><sb:last-page>113</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib49"><ce:label>49</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>M.C.</ce:given-name><ce:surname>Heng</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Local necrosis and interstitial nephritis due to topical methyl salicylate and menthol</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cutis</sb:maintitle></sb:title><sb:volume-nr>39</sb:volume-nr></sb:series><sb:issue-nr>5</sb:issue-nr><sb:date>1987</sb:date></sb:issue><sb:pages><sb:first-page>442</sb:first-page><sb:last-page>444</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib50"><ce:label>50</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Yip</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Chow</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Tai</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Adverse effect of local methylsalicylate ointment on warfarin anticoagulation: an unrecognized potential hazard</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Postgrad Med J</sb:maintitle></sb:title><sb:volume-nr>66</sb:volume-nr></sb:series><sb:issue-nr>775</sb:issue-nr><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>367</sb:first-page><sb:last-page>369</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib51"><ce:label>51</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Joss</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>LeBlond</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Potentiation of warfarin anticoagulation associated with topical methyl salicylate</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann Pharmacother</sb:maintitle></sb:title><sb:volume-nr>34</sb:volume-nr></sb:series><sb:issue-nr>6</sb:issue-nr><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>729</sb:first-page><sb:last-page>733</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib52"><ce:label>52</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Love</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Sammon</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Smereck</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Are one or two dangerous? Camphor exposure in toddlers</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Emerg Med</sb:maintitle></sb:title><sb:volume-nr>27</sb:volume-nr></sb:series><sb:issue-nr>1</sb:issue-nr><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>49</sb:first-page><sb:last-page>54</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib53"><ce:label>53</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Gouin</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Patel</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Unusual cause of seizure</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Pediatr Emerg Care</sb:maintitle></sb:title><sb:volume-nr>12</sb:volume-nr></sb:series><sb:issue-nr>4</sb:issue-nr><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>298</sb:first-page><sb:last-page>300</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib54"><ce:label>54</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Patel</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Ishiuji</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Yosipovitch</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Menthol: a refreshing look at this ancient compound</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Am Acad Dermatol</sb:maintitle></sb:title><sb:volume-nr>57</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>873</sb:first-page><sb:last-page>878</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib55"><ce:label>55</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Vyklicky</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Novakova-Tousova</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Benedikt</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Calcium-dependent desensitization of vanilloid receptor TRPV1: a mechanism possibly involved in analgesia induced by topical application of capsaicin</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Physiol Res</sb:maintitle></sb:title><sb:volume-nr>57</sb:volume-nr></sb:series><sb:issue-nr>Suppl 3</sb:issue-nr><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>S59</sb:first-page><sb:last-page>S68</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib56"><ce:label>56</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Knotkova</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Pappagallo</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Szallasi</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Capsaicin (TRPV1 agonist) therapy for pain relief farewell or revival?</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin J Pain</sb:maintitle></sb:title><sb:volume-nr>24</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>142</sb:first-page><sb:last-page>154</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib57"><ce:label>57</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Mason</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Moore</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Derry</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Systematic review of topical capsaicin for the treatment of chronic pain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>BMJ</sb:maintitle></sb:title><sb:volume-nr>328</sb:volume-nr></sb:series><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>991</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib58"><ce:label>58</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:surname>Drugstore.com</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Topical analgesics</sb:maintitle></sb:title></sb:contribution><sb:comment>Available at:</sb:comment><sb:host><sb:e-host><ce:inter-ref xlink:href="http://www.drugstore.com/search/search_results.asp?N=0&amp;Ntx=mode%2Bmatchallpartial&amp;Ntk=All&amp;srchtree=5&amp;Ntt=topical&plus;analgesics">http://www.drugstore.com/search/search_results.asp?N&equals;0&amp;Ntx&equals;mode%2Bmatchallpartial&amp;Ntk&equals;All&amp;srchtree&equals;5&amp;Ntt&equals;topical&plus;analgesics</ce:inter-ref></sb:e-host></sb:host><sb:comment>Accessed January 10, 2010</sb:comment></sb:reference></ce:bib-reference><ce:bib-reference id="bib59"><ce:label>59</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Chambers</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Reid</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>McGrath</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Self-administration of over-the-counter medication for pain among adolescents</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Arch Pediatr Adolesc Med</sb:maintitle></sb:title><sb:volume-nr>151</sb:volume-nr></sb:series><sb:date>1997</sb:date></sb:issue><sb:pages><sb:first-page>449</sb:first-page><sb:last-page>455</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib60"><ce:label>60</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Van den Bulck</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Leemans</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Laekeman</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Television and adolescent use of over-the-counter analgesic agents</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann Pharmacother</sb:maintitle></sb:title><sb:volume-nr>39</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>58</sb:first-page><sb:last-page>62</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib61"><ce:label>61</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Huott</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Storrow</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>A survey of adolescents&apos; knowledge regarding toxicity of over-the-counter medications</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Acad Emerg Med</sb:maintitle></sb:title><sb:volume-nr>4</sb:volume-nr></sb:series><sb:date>1997</sb:date></sb:issue><sb:pages><sb:first-page>214</sb:first-page><sb:last-page>218</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib62"><ce:label>62</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Warner</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Schnepf</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Barrett</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Prevalence, attitudes, and behaviors related to the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in student athletes</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Adolesc Health</sb:maintitle></sb:title><sb:volume-nr>30</sb:volume-nr></sb:series><sb:date>2002</sb:date></sb:issue><sb:pages><sb:first-page>150</sb:first-page><sb:last-page>153</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib63"><ce:label>63</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Alaranta</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Alaranta</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Heliovaara</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Ample use of physician-prescribed medications in Finnish elite athletes</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Int J Sports Med</sb:maintitle></sb:title><sb:volume-nr>27</sb:volume-nr></sb:series><sb:issue-nr>11</sb:issue-nr><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>919</sb:first-page><sb:last-page>925</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib64"><ce:label>64</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Alaranta</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Alaranta</ce:surname></sb:author><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Helenius</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Use of prescription drugs in athletes</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Sports Med</sb:maintitle></sb:title><sb:volume-nr>38</sb:volume-nr></sb:series><sb:issue-nr>6</sb:issue-nr><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>449</sb:first-page><sb:last-page>463</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:bibliography-sec></ce:bibliography></tail></article>